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SUMMARY 
This medical doctorate thesis contains clinical studies to broaden the 
application and to improve the safety and efficacy of ultraviolet (UV) A 
phototherapies, the main focus being to enhance the current clinical 
practice of topical psoralen photochemotherapy (PUVA.  The thesis 
includes three studies:  
1. The validation of a semi-automated Minimal Phototoxic 
Dose (MPD) Tester for topical photochemotherapy 
Thirty seven psoriasis patients referred to the phototherapy unit at St. 
Woolos, Newport were recruited.  Patients had two sets of minimal 
phototoxic dose (MPD) tests performed on symmetrical, contralateral 
sites on the lower back. MPD test results from a panel of PUVA-lamps 
with a UV-opaque template and windows were compared to those from 
the modified hand-held MPD tester.  The hand-held MPD results were 
linearly related to the PUVA-panel MPD results and this was therefore 
shown to be a convenient and reliable method of assessing MPD.   
However, the difference in MPD between the PUVA lamp and the 
modified handheld MPD tester (CFL TL-10 lamp) was much less than 
predicted from the PUVA action spectrum of previously published 
studies suggesting that formal re-evaluation of the erythema action 
spectrum for PUVA was now appropriate.
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2. The re-evaluation of the erythema action spectrum of topical 
psoralen sensitised skin.  
Re-evaluation of the PUVA erythema action spectrum using aqueous 8-
methoxypsoralen (8-MOP) as used routinely in current clinical practice, 
involved the recruitment of 20 healthy volunteers with so-called skin 
phototypes I – V.  Six UVA irradiations at 10nm intervals between 325 
and 375 nm were randomly allocated to forearm sites and were applied 
using a 10-nm bandwidth irradiation monochromator. The visual 
minimal phototoxic dose (MPD) was recorded on each site at 96 h. This 
study established the erythemal action spectrum for bath/soak PUVA 
therapy as is currently performed and showed the therapeutic action 
spectrum for topical PUVA appeared to be similar to the action 
spectrum of topical PUVA erythema, with a peak sensitivity at 325 nm.           
3. A comparison of topical PUVA regimens in the treatment of 
chronic inflammatory disorders of the hands and feet. 
This study was a within-patient, randomised, assessment-blinded (i.e. 
single-blind), comparison of two treatment regimens involving 
immediate illumination with UVA after immersion in psoralen solution or 
a delay of 30 minutes between soaking hands and/or feet and UVA 
 V 
 
irradiation in the treatment of palmar-plantar dermatoses 
(psoriasis/eczema).  Recruitment was slow for this study; Nevertheless 
7 patients completed the protocol. All patients showed significant 
improvement of their dermatoses during 4-weekly assessments and all 
showed improvement following immediate irradiation though one patient 
with hyperkeratotic psoriasis affecting his soles noted a greater 
improvement following a 30 minute delay. The sample size was too 
small to draw statistically sound  conclusions but strongly suggested 
immediate irradiation was generally suitable, except perhaps in 
hyperkeratotic conditions where the 30 minute delay allowed perfusion 
to the viable epidermis.  A larger patient cohort is now required for 
confirmation
 VI 
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1.1 History of PUVA 
Psoralens and ultraviolet radiation have been used in the treatment of 
cutaneous disease since antiquity.  The ―Ebers Papyrus‖ (circa 1550 
BC), is one of the oldest preserved medical documents. 1  It is currently 
stored in the University of Leipzig library, Germany. The 110-pages 
contain more than seven hundred remedies for various ailments 
including descriptions of how the seeds of the Psoralea corylifolia 
(family Leguminosae), were used for the treatment of vitiligo.1,2  
Physicians and herb specialists from early times used boiled extracts of 
seeds, roots and leaves of these plants to formulate preparations which 
were either applied topically as a paste or ingested two hours prior to 
sun exposure.3 
A similar method of managing vitiligo, was described in the Indian 
sacred book ―Artharva Veda‖ 1400 BC.2  This practise continues to be 
used today by peasants in India where vitiligo remains a major medical 
and social problem. 
The thirteenth century AD, saw the rise of Ibn al-Baitar, one of the 
greatest scientists of Al-Andalus (Andalucia) and a highly regarded 
botanist and pharmacist of the Middle Ages.4  
Ibn al-Baitar described the use of powdered seeds of another plant, 
Ammi majus Linnaeus (which grows throughout the Nile valley as a 
weed), in his book Mafardat Al Adwiya as a ―cure‖ for leukoderma.4 
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Aatrillal (Ammi majus) was commonly used by Ben Shoeib, a Berberian 
tribe, dwelling in the north-western African desert as a remedy for 
leukoderma. Aatrilal, a yellow-brown powder, is still used by Egyptian 
herbalists today as a treatment for vitiligo.5 
Photoactive furocoumarin compounds are contained in many plants 
including lemon, lime, fig, parsnip, parsley, clove and the fruits of A. 
majus and P. corylifolia.2 However, it was 3 millennia later, in 1938 that 
Kuske, a Swiss dermatologist, first described photosensitization of the 
skin by plants due to the presence of natural furocoumarin compounds. 
Kuske isolated bergapten, 5-methoxypsoralen (5-MOP), from the oil of 
bergamot.6 
In 1947 Fahmy, an Egyptian pharmacologist and his student Abu-
Shady, isolated the psoralen compound 8-MOP from Ammi majus.7  
Following on from this work, El Mofty, an Egyptian dermatologist, 
successfully pioneered the use of crystalline 8-MOP both topically and 
orally (40-50mg) followed by sun exposure, achieving repigmentation of 
vitiliginous macules.8   The 1960s and 70s were an era where the basic 
pharmacology of the psoralens was studied. In 1974, Parrish 
successfully introduced a treatment for psoriasis, combining orally 
administered 8-MOP and UVA radiation (320-400nm) using a newly 
developed high intensity artificial UVA light.9 
Honigsmann et al.10  in 1979 reported 5-methoxypsoralen as an 
alternative to 8-methoxypsoralen but with less adverse gastro-intestinal 
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side-effects.  For those patients unable to tolerate oral 8-MOP due to 
nausea and vomiting, 5-MOP PUVA is another alternative. Berg11 et al. 
conducted a double-blind PUVA study to compare efficacy and side-
effects of 5-MOP versus 8-MOP in 38 patients.  At six weeks, patients 
treated with 8-MOP showed greater response than those treated with 5-
MOP.  However, at nine weeks there was no significant difference 
between the two groups.   
Two classic multicentre studies paved the way for the widespread use 
of PUVA in psoriasis. The study by Melski et al. (US Cooperative 
Clinical Trial 1977)12 was conducted in 16 academic dermatology 
departments in the USA. The study assessed efficacy of oral 
methoxsalen photochemotherapy in the treatment of psoriasis.  
Although all centres used the same protocol including dose, light source 
and monitoring of patients, results varied considerably between centres.  
Some centres reported 90% clearance of psoriasis whereas others 
recorded only 40% clearance. Henselar et al.13 reported the results of 
the multi-centre European PUVA study 1981, which assessed efficacy 
of PUVA in achieving remission of psoriasis.  Their findings supported 
those of the US Cooperative Clinical Trial.  In particular, they 
commented that PUVA maintenance therapy may not prevent relapse 
of disease for prolonged periods of time and hence may not be required 
in most patients. 
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Regarding the US cohort and European cohort study the apparent 
differences in skin cancer rates should be viewed with caution.  In USA 
they used systemic PUVA whereas in Europe mainly bath PUVA was 
used. Maintenance therapy for psoriasis patients in the US cohort was 
more commonly used.  The patients in the US cohort also received 
regular follow-up if they had been treated with PUVA, there was no 
control group of patients who did not receive PUVA.  This leads to a 
lead-time bias as the US cohort patients who were more likely to be 
diagnosed earlier with skin cancers.  There was also an ascertainment 
bias as patients with dermatological disease were more likely to be 
diagnosed with skin cancers.  In the European cohort, patients received 
lower PUVA exposure.  PUVA was used for many indications and there 
was little maintenance treatment.  No increased incidence of melanoma 
was found in the European cohort, unlike the US cohort where there 
appeared to be a five-fold annual incidence risk of melanoma in 1997 
and a nine-fold risk of melanoma in 2001.  Furthermore, in the Swedish 
study data from a cancer registry for PUVA treated patients could be 
compared to a control population. Both European and US studies show 
that the risk of non-melanoma skin cancers increase thirty-fold if a 
patient received more than 200 treatments.  However, the high 
prevalence of Phototypes I and II in the US cohort studies may be a 
significant factor for the cancer difference. 
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TABLE 1 SHOWING PUVA HISTORICAL LANDMARKS 
Date  Source  Finding 
 
 
 
 
1550 B.C 
1400 B.C 
 
 
 
 
Eber‘s Papyrus 
Artharva Veda 
 
 
 
 
Psoralea Corylifolia seeds ingested/ applied 
topically as a paste for the treatment of 
leukoderma followed by sun exposure 
13
th
 
Century 
A.D. 
Ibn al-Baitar 
Mafradat Al Adwiya 
Ammi Majus Linnaeus abundantly found in Nile 
Valley – ―cure‖ for leukoderma 
 
 
 
1938 
 
 
 
Kuske 
(Swiss Dermatologist) 
 
 
 
Isolated Bergapten (5-MOP) from oil of 
bergamot.  Skin photosensitization due to 
furocoumarin compounds 
1947 Fahmy (Egyptian 
Pharmacologist) and his 
student AbuShady 
Isolated 8-MOP from Ammi Majus 
1948 El-Mofty (Egyptian 
Dermatologist) 
Pioneered use of crystalline 8-MOP (topically 
and orally) achieving repigmentation of 
vitiliginous macules 
1955 Fitzpatrick et al. Randomised double-blind cross-over trial 
involving 63 volunteers assessing dose-reponse 
to sunlight exposure. Max. Phototoxic effect 1.5-
2hr following oral 8-MOP 
1960 Buck et al. Action spectrum of 8-MOP localised to 360nm 
1965 Mussajo et al. Evidence of covalent photobinding of 
furocoumarin molecules to DNA 
1974 Parrish et al. Oral 8-MOP and high intensity UVA used to 
treat Psoriasis 
1977 US Co-operative Trial 
Melski et al. 
16 Academic Dermatology Departments in USA 
recruited 1308 psoriatic patients to assess 
efficacy of PUVA 
1978 Fritsch et al. Oral retinoid (etrinate) combined with PUVA 
Therapeutic efficacy of PUVA greatly 
potentiated 
1981 European PUVA Study 
Henselar et al. 
Cooperative study - 18 European centres, 
assess efficacy of PUVA in psoriasis.  PUVA 
maintenance therapy little effect on remission 
1987 Edeleson et al. Extracorporeal photochemotherapy (ECP) 
evaluated for CTCL 
1997 
 
2001 
Stern et al. 
 
Stern et al. 
Follow-up study: carcinogenic risk reported on 
US cohort of 1380 patients 
Follow-up study: increased risk of melanoma 
found in original US patient cohort. 
ANCIENT HISTORY 
MODERN HISTORY 
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Fritsch14 introduced the concept of retinoid and PUVA, which he termed 
―Re-PUVA‖ in1978. The combination of PUVA with oral etretinate, an 
aromatic retinoid, potentiated the therapeutic efficacy of PUVA 
significantly by reducing the time, dose of UVA (J/cm2) and number of 
treatments required to achieve clearance of psoriasis.    
Psoralens have also successfully been used as systemic immune-
modifying agents in photopheresis.  Extracorporeal photochemotherapy 
(ECP) was first evaluated by Edelson et al.15 in 1987, for the 
management of erythrodermic cutaneous T-cell lymphoma (CTCL). ECP 
was found to provide high response rates and to improve overall 
survival for the disease. ECP is currently practised in over 150 centres 
worldwide for multiple indications16 including pemphigus vulgaris, atopic 
dermatitis, type I diabetes mellitus, inflammatory bowel disease, 
scleroderma17, systemic lupus erythematosus, epidermolysis bullosa 
acquisita, morphoea18 and nephrogenic fibrosing 
dermopathy/nephrogenic systemic fibrosis19.  ECP may also be used to 
treat acute and chronic organ transplant rejection as well as preventing 
acute organ rejection. 
The procedure involves extracorporeal photoactivation (photopheresis) 
of 8-MOP by passage of blood containing CTCL cells through a UVA 
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exposure system.  The irradiated blood is then re-transfused back into 
the patient. The mechanism of action of ECP remains an area of on-
going research. One theory is that the combination of 8-MOP and UVA 
results in preferential apoptosis of abnormal or activated T-cells thus 
targeting the pathogenic cells of CTCL or graft-versus-host disease 
(GVHD).  There is also evidence that ECP promotes differentiation of 
monocytes into dendritic cells which phagocytose and process the 
apoptotic T-cell antigens.  Following reinfusion of activated dendritic 
cells into the systemic circulation, a resultant systemic cytotoxic CD8+ 
T-cell immune response to the processed apoptotic T-cell antigens 
ensues.  
A major disadvantage of PUVA is the increased risk of skin cancer 
compared to UVB phototherapy. In 1997, Stern et al.20 published data 
on a cohort of 1380 psoriasis patients treated with PUVA in 1975/6.  
They found that the risk of malignant melanoma increased more than 
five-fold particularly in patients who had received 250 treatments or 
more.  A further follow-up study by the same authors in 200121, 
confirmed their initial findings and they described additional melanomas 
in their original patient cohort.  The risk of melanoma increases with 
time in this patient population. 
The use of PUVA has declined significantly with the emergence of 
narrow-band (nb)UVB.  This decline is largely due to the cancer risk, 
which is so much lower for UVB.  PUVA, however still has an important 
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therapeutic role in cases of dermatoses recalcitrant to conventional 
phototherapy and in dermatoses that penetrate deep into the skin. 
 
1.2 Psoralen Photobiology 
 
Psoralens are planar, tricyclic compounds composed of a furan ring 
bound to a coumarin moiety. 
 
 
 
 
 
 
 
                                                              
 
 
 
Fig. 1 Chemical Structure of Psoralen22  
R1 = H R2 = H Psoralen 
R1= OCH3 R2 = H 5-Methoxypsoralen     
(5-MOP) 
R1 = H R2 = 
OCH3 
8-Methoxypsoralen      
(8-MOP) 
R1 
R2 
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The planar, aromatic structure of psoralens together with their 
hydrophobic nature, facilitate their intercalation with DNA bases.23 
Psoralen has been shown to enhance the generation of reactive oxygen 
species and free radicals in the absence of light and to possess pro-
oxidative effects24.  However, psoralen alone in the absence of 
ultraviolet light has no effect on the function of DNA synthesis of human 
cells grown in vitro25. This finding is supported by a study of S-180 
(murine sarcoma) cells, in which neither the psoralens nor UVA light 
alone inhibit cell growth but together act synergistically26.  
The principle theory of psoralen photobiology revolves around the 
impact of adduct formation on cellular properties and function. The most 
frequently occurring adducts are those with thymine-psoralen; cytosine-
psoralen adducts occur less efficiently.  When irradiated with UVA light, 
a 2 + 2 photocycloaddition reaction occurs with pyrimidine bases, 
particularly thiamine.  This occurs between the 4‘,5‘double-bond furan-
side of psoralen and the 5,6 double-bond of thymine.  This may involve 
one or both strands of DNA resulting in 2 types of lesions: monoadducts 
or interstrand cross-links, which are responsible for the short and long-
term effects of PUVA respectively.  Interstrand cross-links occur 
following cycloadditions between one psoralen molecule and two 
pyrimidine bases on two complementary DNA strands.  The cross-
linking process depends upon the structure of the psoralen.  Linear 
furocoumarins form cross-links more efficiently than angular 
furocoumarins.23
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Figure 2: Illustrating Monoadduct Formation and Interstrand Cross-linking between 
psoralen and DNA 
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 The initial hypothesis was that these reactions had an anti-proliferative 
effect.  In psoriasis, therefore, PUVA therapy would induce 8-MOP DNA 
photoadduct formation slowing cellular replication.  However, Johnson 
et al.27 showed that keratinocytes were very resistant to the effects of 
PUVA therapy whilst cytokine-releasing lymphocytes in the epidermis of 
psoriasis patients were much more sensitive.  In addition, there was 
virtual elimination of epidermal CD3+ T-cells in psoriatic skin.28   
Whilst comparing the effects of Trimethyl Psoralen (TMP) to 8-MOP, 
Coven et al.21 found TMP to be nearly 10,000-fold more lymphotoxic 
compared to 8-MOP.  Further work needs to be carried out to establish 
the carcinogenicity risk of TMP.  Coven et al. suggest this ―potent 
lymphotoxic treatment may prove to be one of the safest and most 
effective treatments for psoriasis.‖28   
Although DNA psoralen photochemistry is well characterised, psoralens 
also react with proteins and other cellular constituents.  Studies to 
determine the affinity of 8-MOP to bind with epidermal lipids, proteins, 
and DNA/RNA following PUVA treatment showed 17% of the 8-MOP 
was bound to DNA, whilst the vast majority was bound to proteins 
(57%) and lipids (26%).29  A common finding when assessing PUVA 
effects on proteins, however, was that much greater doses of 8-MOP 
and UVA are required to produce a biological effect than relatively small 
doses necessary to induce DNA damage.30   
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1.3 Psoralen Erythema Action Spectrum 
For PUVA to be successful, a number of elements need to be 
optimised.   These include: choice of psoralen, mode of administration 
for psoralen, timing of psoralen administration relative to UVA exposure, 
dose of UVA, rate of application of UVA and spectrum of UVA 
administered.   Thus, the action spectrum of psoralen within UVA is 
defined as the rate of physiological activity (erythemal response) plotted 
against light wavelength (UVA 320nm-400nm). 
 The published action spectrum of psoralen-induced erythema enables 
the calculation of the erythemal efficacy of any UV source where the 
emission spectrum of the lamp is known or can be measured.25-30 
However, the action spectrum of 8-MOP differs markedly from its 
absorption spectrum.31 Potential reasons for this are psoralen or 8-MOP 
under-go chemical changes upon their incorporation into the skin and 
exposure to UVA and the action spectra within the skin will differ 
according to the absorption spectra of the chromophores they target. 31 
The UV absorption spectra for psoralen and 8-MOP compounds have 
been reported by Fowlks32 as having maximal absorption at 
approximately 220nm, 245nm, and 295nm (with a shoulder at 330nm) 
for psoralen and  220nm, 250nm, and 310nm for 8-MOP.   
In 1940, Kuske demonstrated that topically applied psoralens led to 
photosensitisation with the 334nm and 366nm lines of the mercury arc 
spectrum from a monochromator.  Stegmaier33 (1959) showed that 
CHAPTER ONE 
Introduction 
13 
 
following ingestion of 8-MOP, erythema developed after subsequent 
exposure to fluorescent lamps which emitted the majority of their energy 
between 320 – 360 nm. In 1960, Buck et al.34 used 1% 8-MOP applied 
topically on human skin; Pathak35 (1961) administered 8-MOP orally to 
guinea pigs.  Both Buck et al. and Pathak localised the peak erythemal 
action spectrum of 8-MOP to 360nm.   
Later studies conducted by Owens36 et al. (1968) administering oral 8-
MOP to guinea pigs and Nakayama37 et al (1974) using topical 
application of both 8-MOP and TMP on guinea pigs both noted that 
maximum sensitivity occurred at 330 nm.  
This discrepancy in reported erythemogenicity led to a re-evaluation of 
the psoralen erythema action spectrum by Cripps38 et al. (1981).  Cripps 
concluded that peak sensitivity for 8-MOP was 330nm and for TMP was 
335nm.  The study used 8-methoxy psoralen at 1% dissolved in 
acetone and then in ethanol and applied directly to the skin, followed by 
irradiation with various wavelengths of UVA. No details were provided 
for the time between application of psoralen and UVA irradiation were 
given.38  
This scenario differs greatly from present clinical practice, where the 
skin is immersed in an aqueous solution of 8-methoxypsoralen at 
37ᵒC39 for 15 minutes, followed by UVA irradiation within 30 minutes.  
The study by Schempp40 et al. showed there was a marked, significant 
reduction in erythema after 60 minutes delay between soaking in an 8-
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MOP bath and irradiation and no erythema was detected after 180 and 
360 minute delay.  Thus, it is timely to re-assess the action spectrum for 
PUVA in the context of current clinical practice for this treatment. 
A general problem in comparing studies of erythemal effectiveness is 
the definition of minimal erythemal or phototoxic dose, the outcome 
measure used to define the photosensitising potential of UV treatments 
on skin (both psoralen-sensitised and non-sensitised). 
Early studies used a definition of minimal erythema as skin with minimal 
redness described as even or confluent with sharp borders. Later 
definitions describe minimal erythema as ―barely perceptible‖, dropping 
the requirement for the irradiated site to have confluent erythema with 
sharp borders.  
Reported differences in psoralen formulation, application time, body 
site, skin phototypes and time to read erythema make the 
photosensitising outcome measures somewhat heterogeneous, and 
restrict conclusions from comparison of studies to be relatively 
generalised.
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1.4 Pharmacokinetics of Psoralens 
Three psoralens are used for PUVA therapy, the most commonly used 
being 8-MOP; 5-MOP and 4,5‘8-trimethylpsoralen  are also used.  
1.41 Systemic Psoralen 
Approximately 75-80% of 8-MOP is reversibly bound to serum albumin 
and distributed to all organs.  This binding is short-lived in the absence 
of UVA exposure and the drug is metabolised in the liver and excreted 
as inactive metabolites in urine.41   The rate of intestinal absorption of 
psoralens is dependent upon several factors including concomitant 
drugs, food intake and physical characteristics of the preparation.   
Food intake, particularly of high fat content, decreases the absorption of 
psoralens42.  Psoralen undergoes first-pass metabolism and may result 
in interindividual variability in plasma levels after a fixed dose of 
methoxsalen.43 Drugs that induce cytochrome P-450 enzymes may 
decrease the biologic effect of PUVA.  5-MOP is less water soluble than 
8-MOP and has an absorption rate approximately 25% that of 8-MOP.44  
Dissolved preparations (soft gelatine capsules) are better absorbed 
than crystalline formulations.  The former yields peak serum levels in a 
relatively reproducible time whereas wide time variability occurs with 
crystalline formulation.45  In contrast, the pharmacokinetics of topical 8-
MOP depend on the method of application.  0.15% 8-MOP emulsion or 
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solution applied to large body areas results in plasma levels 
comparable to those achieved with oral administration, whereas plasma 
levels after whole body bath PUVA treatment are very low.444 
1.42 Topical Psoralen 
Topical PUVA was first used to treat palmoplantar psoriasis in 1974.46 
Further studies have been published with variable results.47,48,49    The 
treatment schedules vary considerably with regards to method of 
psoralen application and the time interval between psoralen application 
and UVA irradiation.  The advantage of immersion (soak) PUVA is the 
epidermis is fully hydrated and overcomes problems associated with 
variable application as occurs in paint PUVA.  The degree of hydration 
is known to affect permeability of the stratum corneum.50  
The optimal time for UVA irradiation on palmoplantar skin following 
application of topical 8-MOP psoralen or by immersion appears to be 
related to the lag time.50   That is the time taken for a substance with 
diffusion properties to appear in considerable quantity in the viable 
epidermis. This is related to the thickness of the stratum corneum and 
the diffusion coefficient.   Abnormalities of the stratum corneum as in 
psoriasis or eczema may lead to an increased permeability to psoralens 
when compared with unaffected skin.  Diffusion is influenced by factors 
including vehicle characteristics or the presence of emollients on the 
surface of the skin.   The greatest penetration occurs with solutions and 
emulsions.51 
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Penetration kinetics of 8-MOP into human skin have been investigated 
using in vitro conditions.51 8-MOP tissue concentration increases with 
time.   The lag time in palmoplantar skin is increased to 30-40 minutes 
before maximum UVA sensitivity is reached and is followed by 
sustained sensitivity for approximately an hour.50  This implies that 
immediate irradiation of these sites is  unsuitable.  The increased 
thickness of the stratum corneum on both palmar and plantar sites 
compared to other body sites, acts as a drug reservoir and may explain 
the sustained activity providing an optimum therapeutic window from 
30-110 minutes after the soak. 
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1.5 Minimal Phototoxic Dose (MPD)  
The MPD is the lowest dose of UV radiation of psoralen-sensitised skin 
which causes a just perceptible erythema52.  The MPD may also 
unmask previously unidentified photosensitivites due to dermatoses or 
phototoxicity secondary to concurrent medications. The initial UVA dose 
should, when possible, be based on an MPD test.  This helps to identify 
the optimal starting dose of PUVA – thus avoiding either painful 
erythema or, conversely, under-treatment.52 If the extent of disease 
precludes MPD testing, then the initial dose can be based on skin 
phototype, although this is not ideal (see below).   
ASSESSING MPD  
Traditionally, MPD‘s have been examined at 72 hours when it was 
believed that peak PUVA erythema was maximal53,54,55  However, 
Ibbottson and Farr demonstrated that peak PUVA erythema using oral 
8-methoxypsoralen (8-MOP) occurs at 96 hours.56  Man et al. showed 
the optimal time to assess topical 8-MOP MPD is 120 hours.57  MPD 
assessment during or beyond 120h is best avoided due to confounding 
effects of the development of pigmentation57.  Their recommendation 
was that topical 8-MOP MPD should be read four days (96 hours) after 
exposure.  40% of the MPD is in widespread clinical usage as the initial 
treatment dose at the start of a course of PUVA therapy.57 Subsequent 
dose increments of 20-40% are recommended, with an increase if 
tolerated, at every treatment.52  
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The traditional method of assessing MPD is cumbersome and time-
consuming for both patients and staff.  Several small areas of skin are 
exposed to increasing doses of UVA from a panel of UVA lamps.  This 
―open‖ source is associated with the potential for errors including UV 
source non-uniformity due to curvature of the test site, patient 
movement, incorrect positioning of the patient leading to incorrect 
distance between the skin and UVA lamps and exposure timing errors. 
A device that overcomes many of these difficulties is the minimal 
erythema dose (MED) tester used for UVB. This uses a compact 
fluorescent tube (CFL) in a handheld housing as the source and a UVB 
opaque template with 10 x 1-cm-diameter apertures. The output of nine 
of these apertures is successively attenuated by a factor of 1.25 by 
steel shaver-type foils.  This device will be discussed in more detail in 
Chapter 2.
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1.6 Skin Phototypes 
The concept of skin phototype was proposed by Professor Thomas 
Fitzpatrick the Chair of Dermatology at the Massachusetts General 
Hospital in Boston, in 1978 as a way to subdivide human beings by their 
tanning and erythemal responses to sun exposure.   The Fitzpatrick 
Skin Type58 (phototype), sometimes referred to as the Boston 
Classification of skin type, correlates an individual‘s skin colour with 
their ability to burn or tan when exposed to sunlight. Patients were 
asked two specific questions about their responses to three minimal 
erythema doses (MED) or approximately 45 – 60 minutes of noon 
exposure in northern latitudes (20º- 45º) in early summer. 
1. ―How painful is your sunburn after 24 hours?‖ 
2. ―How much tan will you develop in a week?‖ 
However, this relies on an individual‘s recollection of past observations, 
making the accurate determination of skin types very difficult in practice.  
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Table1.2: Fitzpatrick Skin Phototype 
Skin 
Phototype 
Constitutive Colour* 
(unexposed skin 
colour) 
Sunburn & Tanning 
History 
Sensitivity 
to UV 
I Ivory White Always Burns, never tans Very 
Sensitive 
II White Always Burns, tans 
minimally 
Very 
Sensitive 
III White Burns minimally, tans 
gradually and uniforml 
Sensitive 
IV Light Brown, Beige-Olive Burns minimally, always 
tans well 
Minimally 
Sensitive 
V Moderately Brown Rarely Burns, tans darkly Rarely 
Sensitive 
VI Dark Brown Never Burns, tans darkly Least 
Sensitive 
* The constitutive skin colour is genetically determined by the amount of 
cutaneous melanin. 
 
However, Schiener et al.59  showed that skin phototype is not a suitable 
indicator for the initial UVA dose in PUVA bath photochemotherapy. 
This is supported by Kraemer et al.60 Mean MPD values were greater 
than the values attributed to those used for the different phototypes. 
Patients being treated with PUVA would therefore receive lower initial 
UVA doses than was necessary, prolonging treatment and potentially 
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subjecting individuals to late side effects.  Therefore, phototype alone is 
not a good parameter to define the initial UVA dose.  
1.7 ADVERSE CLINICAL EFFECTS OF PUVA 
 
1.71 Short-term 
 
Nausea 
 
Nausea is the most common adverse reaction following oral 8-MOP 
(30% of patients) and vomiting (10% of patients).  This may require 
reduction in the dose of oral 8-MOP or in severe cases discontinuation 
of treatment.  These side-effects are encountered more frequently with 
liquid rather than crystalline preparations.  Conversely oral 5-MOP is 
much less frequently associated with nausea.61 
Patients are advised to take oral 8-MOP with a small amount of food 
with a high fat content or milk to prevent or reduce nausea.  This may 
decrease the absorption of psoralens.  Ginger has also been used to 
reduce the nausea.   
 Erythema 
Excessive phototoxicity varying from intense delayed erythema to bulla 
formation may occur.  This may occur in approximately 10% of patients 
during the clearance phase.62 Management is largely symptomatic 
including liberal use of emollients, anti-pruritic agents and cool baths.   
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If large areas of skin are affected, systemic symptoms of excess 
photosensitivity including fever and general malaise may occur. Non-
steroidal anti-inflammatory drugs and topical or systemic corticosteroids 
may be required to alleviate symptoms. 
 Subacute phototoxicity presents as a diffuse scaly erythema with 
intense pruritus and may occur at any time during a course of PUVA 
therapy even if the dose of UVA has remained stable for a period of 
time.62  An important feature of subacute phototoxicity is the sparing of 
body areas naive to UVA during treatment e.g. axillae. Management 
involves conservative measures as above and possibly a temporary 
cessation of PUVA therapy.  PUVA may be resumed at a dose of UVA 
30-40% lower than the previously used dose, with gradual increments 
as tolerated by the individual.  
Pruritus and Skin Pain 
Mild pruritus secondary to dry skin during PUVA therapy is common.  
Liberal use of emollients is generally sufficient to relieve this.  Intense 
pruritus ―PUVA-Itch‖ is commonly described as a deep, burning itch 
occurring in the presence or absence of erythema.  This usually begins 
on the outer aspects of extremeties, buttocks and, in women, on the 
breasts.  An uncommon complication of PUVA therapy is persistent skin 
pain.63 64  Pruritus and skin pain have been postulated to occur as a 
result of phototoxic damage of the dermal nerve endings.65 
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Other Short-Term Adverse effects 
This may include reactivation of herpes simplex, triggering PLE, photo-
onycholysis and melanonychia.66 
1.72 Long-Term 
Photoageing 
Skin ageing may be differentiated into intrinsic (chronological) ageing 
and photoageing67.  Chronic exposure to PUVA results in dry skin, 
irregular pigmentary changes, telangiectasia, wrinkle formation, 
yellowish skin discolouration, loss of elasticity and actinic keratoses.  
Additionally, profuse dark lentigines – PUVA lentiginosis may occur. 
Photoageing of darker Asian skin differs from that of whiter Caucasian 
skin primarily due to melanocytic function.  Ethnicity, genetic differences 
and sun exposure habits also modify skin structure and function.  
Clinically the dyspigmentation and wrinkling responses associated with 
photoageing differ between Asian and Caucasian skin68. Initial beliefs 
that Asian skin photoageing mainly comprised of pigmentary change 
rather than wrinkling is disputed69.  Further investigation is required to 
elucidate the inherent characteristics of Asian skin, and on the aging 
and photoageing processes in Asians. 
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Photocarcinogenesis 
The multi-centre Photochemotherapy Follow-up Studies reported by 
Stern et al.70 showed that large cumulative doses greatly increase the 
risk of skin cancer.  Interestingly, there have been no reports of such 
risk in vitiligo patients treated with PUVA.   
Squamous cell cancer remains the primary cause of cancer morbidity 
and mortality in psoriasis patients with skin types I and II treated with 
PUVA. SCC metastases occurred in 4- 5% of these patients.70  There is 
also in an increased risk of SCC in patients receiving long-term 
ciclosporin subsequent to PUVA. 
Male genitalia are particularly high risk sites for development of SCC 
especially if previously treated with tar and UVB prior to PUVA, 
highlighting the need for shielding during treatment71.  A retrospective 
study involving 5400 patients treated between 1978–1998, showed no 
cases of genital cancer despite no genital shielding during UVA 
exposure.72  There was a significant increase in the incidence of truncal 
basal cell carcinomas (BCC) in patients receiving a high number of 
treatments.  However, BCCs are easily treatable and have a low 
associated morbidity. 
Of the 1380 patients enrolled in the U.S. multi-centre study73, 23 
patients developed 26 invasive or in-situ melanomas since first followed 
in 1975. This occurred in patients receiving the highest doses of therapy 
and the longest follow-up. These two factors may be interrelated as an 
CHAPTER ONE 
Introduction 
26 
 
increased incidence of melanoma has not been observed in other 
studies of patients managed with PUVA.  The study published by 
Hannuksela et al74. involving 944 Swedish and Finnish psoriasis 
patients receiving bath PUVA with TMP, did not show an increased risk 
of SCC‘s or cutaneous melanoma.  Furthermore, no association 
between cutaneous carcinoma and 8-MOP bath PUVA was detected in 
158 Finnish patients75.  
This variability in apparent cancer risk may be due to differences in 
cumulative exposure to PUVA phototherapy, ethnicity, treatment 
protocols, prior exposure to other carcinogens including x-irradiation, 
and attitudes toward sun exposure.  Follow-up duration of these 
patients also needs to be taken into account.  
Ocular Effects  
UVA penetrates the lens and accelerates cataract formation by 
psoralen-protein photoadduct formation in animal models. However, in 
clinical studies, there has not been a dose-related increase in cataract 
formation76.  Eye protection however, remains mandatory during 
treatment. UVA-opaque glasses are worn by patients receiving 
systemic psoralens until the evening of the day of treatment.  
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Other Effects 
Cardiovascular disease, non-cutaneous neoplasms including 
lymphomas, hepatitis77,78 or the occurrence of ANA antibodies79 are not 
associated with PUVA therapy80.   
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1.8 Clinical Indications PUVA81 
 
Therapy of Disease Induction of tolerance in 
photosensitivity conditions 
Psoriasis 
Palmoplantar pustulosis 
Atopic dermatitis 
Polymorphic Light Eruption‡ 
Solar Urticaria‡ 
Chronic Actinic Dermatitis*‡ 
Mycosis Fungoides Hydroa Vacciniforme*‡ 
Vitiligo Erythropoietic protoporphyria*‡ 
Generalised Lichen Planus  
Cutaneous Graft Versus Host Disease 
Prurigo Nodularis 
Urticaria Pigmentosa 
Generalised Granuloma Annulare 
Localised Scleroderma* 
Pityriasis Lichenoides (acute & chronic)* 
 
Lymphomatoid papulosis*  
Langerhans Cell Histiocytosis*  
Purpuric Pigmented Dermatitis* 
Pityriasis Rubra Pilaris*‡ 
 
Table 1.3 PUVA RESPONSIVE DISEASE 
 
 
 
 
*Limited to small number of patients 
‡
May flare 
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Psoriasis 
Psoriasis is a common, chronic, inflammatory skin disease 
characterised by scaly erythematous papules and plaques.  There are 
various clinical patterns of psoriasis including:   
 Psoriasis vulgaris – small/large plaques occurring on extensor 
surfaces  
 Guttate psoriasis – sudden onset widespread, crops of small, 
drop-like, scaly papules and plaques, usually precipitated by 
streptococcal tonsillitis/pharyngitis. 
 Palmoplantar pustulosis;  
 Generalised pustular psoriasis 
 Flexural psoriasis 
 Erythrodermic psoriasis   
Prevalence of psoriasis varies between ethnic groups, but is estimated 
to affect approximately 2% of the population worldwide.  Susceptibility 
to the condition is inherited.  Approximately 30% of patients with 
psoriasis vulgaris have an affected first-degree relative.  Although no 
single psoriasis gene has been identified, at least 9 chromosomal loci 
have been linked to psoriasis.  The major genetic determinant of 
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psoriasis is found on Chromosome 6p, designated PSOR 1.  The 
absence of 100% concordance in monozygotic twins indicates that 
environmental factors contribute to expression of psoriasis in 
susceptible individuals.  Patients with psoriasis are at greater risk of 
developing other immune-mediated diseases including sero-negative 
arthritis and Crohn‘s disease.  Patients are also more likely to develop 
the metabolic syndrome.    
Traditionally, psoriasis is managed in step-wise manner.  Step 2 often 
gets omitted because of poor provision of phototherapy across the UK.  
TOPICAL:
PHOTOTHERAPY:
SYSTEMIC:
BIOLOGICS
• Acitretin
• Azathioprine
• Ciclosporin
• Fumaric Acid Esters
• Methotrexate
• Mycophenolate Mofetil
• nb-UVB
• PUVA
• Steroids
• Vitamin D analogues
• Dithranol
• Coal Tar
• Emollients
STEP 1
STEP 2
STEP 3
STEP 4
  
Figure 1.3 Stepwise Management of Psoriasis 
 
Increasing Efficacy 
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Topical treatments are suitable for limited disease.  The main 
drawbacks are that these treatments can be time-consuming and 
compliance with the topical regimes may become a problem. 
Patients with widespread psoriasis, in particular guttate psoriasis, often 
benefit from a course of phototherapy.  NB-UVB therapy has been used 
successfully in the treatment of psoriasis and is generally accepted to 
be first line compared to PUVA.  Furthermore due to safety nbUVB is 
the first-line therapy in pregnant patients with plaque and guttate 
psoriasis who need treatment.82  Patients who respond poorly to nbUVB 
may then be offered PUVA (but not in pregnancy).  
PUVA is one of the most effective therapies available for widespread 
psoriasis. Fourteen hundred and eight patients were included in the 
European Cooperative Clinical Trial assessing the efficacy of oral 
methoxsalen with UVA phototherapy for the treatment of psoriasis.12  
88% of patients cleared following twice or three times weekly PUVA 
treatments. A course of 24 treatments with PUVA often results in 
clearing of psoriasis, with varying remissions lasting between 3 – 6 
months.83  
Gordon et al.85 reported a randomised comparison of nbUVB and PUVA 
for 100 patients with plaque-type psoriasis.  Patients were randomly 
allocated to receive twice weekly nbUVB (TL-01) or PUVA.  Clearance 
of psoriasis was achieved in a significantly greater proportion of PUVA-
treated patients (84%) compared to TL-01 (63%), with significantly 
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fewer treatments.  Six months after completion of treatment, 35% of 
patients treated with PUVA compared to 12% of patients treated with 
TL-01 remained clear84.  A double-blind, randomised, single-centre 
study comparing nbUVB with PUVA for the treatment of 93 psoriasis 
patients, also demonstrated that PUVA treatment achieved clearance in 
more patients with fewer treatment sessions than does nbUVB.  In this 
study, PUVA resulted in longer remission time than nbUVB.85   
There are also studies supporting similar efficacy for nbUVB and oral 
PUVA.  Van Weelden86 et al. reported that twice weekly nbUVB was as 
effective as twice weekly oral 8-MOP PUVA in ten patients after four 
weeks of treatment.  Similarly, Tanew87 et al. confirmed that both 
treatments were equally effective when administered thrice weekly but 
suggested that oral 8-MOP PUVA was superior for patients with severe 
plaque psoriasis.  A further randomised parallel study by Markham88 et 
al. involving fifty-four patients found that twice weekly PUVA was as 
effective as thrice weekly nbUVB in achieving clearance of chronic 
plaque psoriasis. 
However, a retrospective study examining the remission rates between 
PUVA and NBUVB, found no statistically significant difference between 
the two.  Although, PUVA-treated patients remained clear for a period of 
about 88 days longer than patients treated with nbUVB89. 
PUVA may be administered alone or in combination with other 
treatments to minimise PUVA dosage.  There are conflicting reports 
CHAPTER ONE 
Introduction 
33 
 
regarding remission periods when topical steroids are combined with 
oral PUVA.  One study found this combination resulted in faster 
clearance without reducing the period of remission; whilst another study 
found the addition of topical steroids resulted in shorter remissions.90,91 
The combination of topical vitamin D analogues (calcipotriol) with PUVA 
has been reported to decrease duration of PUVA therapy with an 
improved clinical response.92     
A potent therapeutic regimen for psoriasis involves the combination of 
PUVA with systemic retinoids (RePUVA).  RePUVA reduces the 
number of exposures as well as the total cumulative UVA dose and is 
particularly useful in ―poor PUVA responders.‖  An additional advantage 
of systemic retinoids is that they may suppress the development of non-
melanoma skin cancers.93   
Isotretinoin and PUVA was reported to provide a good response in four 
young adult females.  This is particularly important for women of child-
bearing potential for whom acitretin is contraindicated94.  Women are 
still advised to avoid pregnancy for at least 31 days after stopping 
isotretinoin.  
A recent randomised comparison of acitretin with narrow-band (nb)UVB 
and acitretin with PUVA in 60 patients with moderate-severe plaque 
psoriasis was undertaken.  Efficacy was assessed using PASI scores 
by a blinded observer.  Clearance was achieved in 56.6% of patients 
with reUVB compared to 63.3% in rePUVA group.  This cohort of 
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patients remained clear three months after completing treatment, 
irrespective of whether they had received nbUVB or PUVA95. 
Studies have compared bath-water delivery of 8-MOP to oral 8-MOP.  
Lowe96 et al. found bath PUVA to be as effective as oral PUVA, 
requiring less UVA and no associated systemic side effects such as 
nausea. The study by Collins97 et al. involving 44 patients confirmed 
these findings.  The therapeutic efficacy of bath PUVA may well be due 
to the higher penetration of psoralens through abnormal stratum 
corneum over psoriatic plaques compared to normal peri-lesional skin.  
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Palmoplantar Putulosis (PPP) 
Palmoplantar pustulosis (PPP) is a chronic condition characterised by a 
vesiculopustular eruption affecting the palms and soles.  PPP may be 
associated with autoimmune diseases including thyroid disease and 
diabetes mellitus.  Genetic studies on PPP however, have not shown a 
link to the same loci as psoriasis vulgaris.  The relationship between 
these two conditions is controversial. 
Treatment of PPP is often challenging and unsuccessful.   
Nevertheless, a reasonable degree in efficacy of oral PUVA when 
compared to placebo has been established in the management of PPP. 
Both Murray98 et al. (1980) and Rosen99 et al. (1987) found that patients 
with PPP improved on systemic PUVA. In Murray‘s cohort of patients, 
all 22 showed improvement and 12 patients had clearance of disease.  
Results for placebo showed improvement in 12 patients and no patients 
had clearance.  In Rosen‘s within-patient comparison of oral PUVA 
versus placebo, 9 of 14 (64%) and 2 of 14 (14%) PPP patients showed 
improvement with oral PUVA and placebo respectively.  However, only 
3 of 14 patients had clearance of disease with oral PUVA.   
 There does not appear to be any benefit of topical PUVA in PPP. 
Layton100 et al. (1991) and Matsunami101 et al. (1990) failed to show any 
benefit of topical PUVA over placebo.  These findings are consistent 
with those of Lassus102 et al.1985.  
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There is no additional advantage of using short-term PUVA following 
induction of remission with topical steroid under occlusion. Nielsen103 et 
al. 1995, showed that a third of PPP patients (3 of 9) receiving short 
term PUVA did not relapse within one year compared to 6 of 13 patients 
who did not receive further intervention. 
 Two studies have compared PUVA with etretinate. The study by Rosen 
comparing oral PUVA to etretinate did not show a definite benefit of 
retinoids over PUVA or vice versa.  Lassus‘ study used topical and 
systemic PUVA.  Lassus found the use of etretinate to be more 
effective. Yet the results of Lassus‘ study showed generally lower 
response rates for all PUVA modalities than other studies. Overall, 
there does not appear to be a significant difference between PUVA and 
retinoids.     
This is supported by a Cochrane Systematic Review of interventions for 
chronic palmoplantar pustulosis in which twenty-three trials involving 
724 people were included.   The evidence supporting the use 
of systemic retinoids, showed an improvement rate difference of 44%, 
(95% confidence interval [CI] 28% - 59%). Oral PUVA showed an 
improvement rate difference of 44% (95% CI 26% – 62%). However, 
when the modalities are combined, retinoids and PUVA (rePUVA), the 
outcome is superior to a single treatment modality104. 
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Atopic Dermatitis  
Atopic Dermatitis (AD) is an intensely pruritic skin condition that usually 
starts around three months of age.  AD clears in approximately 50% of 
children by puberty.  In others, AD is persistent or recurrent in adult life.  
Clinically, AD is characterised by xerosis (dry skin), pruritus, 
eczematous lesions and lichenification. AD is more commonly 
associated with a personal or family history of atopy (asthma, eczema 
or allergic rhinitis); however environmental factors also play a role.  The 
pathophysiology of AD is poorly understood.  Defective epidermal 
barrier function (due to loss-of-function mutations in the gene encoding 
fillaggrin) and an imbalance of T lymphocytes (TH2 predominance) 
causing an increase in IgE sensitisation play a major role. 
Patients with moderate to severe (including erythrodermic) eczema 
have benefitted from PUVA.  Oral PUVA has successfully been used to 
treat severe atopic eczema in adolescents.  14 out of 15 children had 
initial clearance, nine of whom achieved complete remission. 
Resumption of normal growth in children previously growing poorly 
occurred105.  In a subsequent update of oral PUVA, to treat severe 
childhood eczema, thirty-nine out of fifty-three children who received 
twice weekly treatment, achieved clearance or near-clearance after an 
average of 9 weeks106. Bath PUVA markedly improved pruritus, night-
time rest and severity of lesions in 29 adults with severe atopic 
dermatitis.  Three patients discontinued treatment due to aggravation of 
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their disease.  The patients received thrice weekly treatments for a 
maximum of 30 sessions107. However, in comparison to psoriasis, 
atopic dermatitis is more difficult to treat and generally requires a 
greater number of treatments. Patients are younger and relapse rates 
are high.  
In a randomised control trial comparing nbUVB, UVA and fluorescent 
light exposure for adults with atopic dermatitis, nbUVB was more 
effective as an adjunctive treatment for moderate to severe atopic 
eczema. The treatment was well tolerated by most patients.108 
A systematic review of photo(chemo)therapy in the management of AD, 
including nineteen randomised controlled studies (905 participants) 
highlighted the need for further well-designed, adequately powered 
RCTs.109  A meta-analysis was not feasible due to the heterogeneity of 
RCTs due to small sample sizes, varying study quality and occasionally 
the absence of direct comparisons.  The conclusion on the evidence 
provided was that UVA1 and nbUVB appeared the most effective 
treatment modalities for the reduction of clinical signs and symptoms. 
There is also evidence suggesting that UVA/UVB was more effective 
than UVA and broadband-UVB for the improvement of clinical 
symptoms, but not compared with UVA1.110 
UVA1 is a promising phototherapeutic modality for acute severe, atopic 
eczema. As for nbUVB phototherapy it is administered for a limited 
period of time (ten to fifteen exposures). Efficacy for UVA1 in eczema 
CHAPTER ONE 
Introduction 
39 
 
appears to be dose-dependent111.  A detailed discussion on UVA1 is 
beyond the scope of this thesis. 
 
Mycosis Fungoides (Cutaneous T-Cell Lymphoma–CTCL) 
Cutaneous T-cell lymphomas (CTCLs) are a group of 
lymphoproliferative disorders characterised by a neoplastic clonal 
proliferation of T-cells localised to the skin.  Mycosis fungoides is the 
commonest CTCL.  The choice of treatment and prognosis are related 
to the stage of the disease112. 
 Stage I – patches and plaques involving less than 10% (IA) or 
more than 10% (IB) of the skin 
 Stage II – as stage I, with non-malignant lymphadenopathy (IIA) 
or cutaneous tumours (IIB) 
 Stage III – generalised erythroderma 
 Stage IV – malignant infiltration of blood (IVA), lymph nodes 
(IVA2), viscera (IVB) 
 Gilchrest et al. were the first to report successful use of PUVA for 
CTCL113. All nine patients treated with oral 8-MOP and UVA responded 
well; four remained in complete remission.  Based on the data of five 
studies and a total of 244 patients, Hermann114 et al. calculated the rate 
of complete remission after an initial course of PUVA to be 90% for IA, 
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76% for stage IB, 78% for stage IIA, 59% for stage IIB%, and 61% for 
stage III (staging according to the 1979 Bunn Classification).   
The relapse rate and disease-free survival for MF treated with PUVA is 
less well documented.  Querfeld et al. published data on 66 CTCL 
patients (stage IA – II) who achieved complete remission after an initial 
course of PUVA.  Patients were followed-up for up to 242 months.  The 
5- and 10-year disease-free survival rates for patients with T1 disease 
were reported as 56% and 30%, respectively, and 74% and 50% for 
T2.115 
The results of a recent multinational survey amongst dermatologists 
showed that 88% of respondents used PUVA as maintenance therapy 
after disease clearance has been achieved. However, there was no 
consensus on frequency, UVA-dose or duration of PUVA therapy.116  
This is despite the published data on carcinogenic risk associated with 
PUVA (Stern et al.).  Furthermore, EORTC have recently published 
their consensus report and suggest avoiding maintenance PUVA. 
For patients with advanced disease (tumour stage or lymph node 
involvement), PUVA may be used in combination with other systemic 
agents.  These include: interferon-α (IFN-α), retinoids (isotretinoin, 
etretinate, acitretin) and more recently bexarotene, (a retinoid that binds 
to the nuclear retinoid X receptor). Although these drugs are effective 
monotherapeutic agents, combination with PUVA is likely to have an 
additive effect. However, whether any PUVA combination is superior to 
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PUVA alone in terms of clinically relevant endpoints (e.g. toxicity, 
disease-free survival, overall survival) remains unanswered117. 
   
Vitiligo 
Vitiligo is an idiopathic, common acquired pigmentary condition and can 
have a profound psychosocial affect on individuals.  Loss of epidermal 
melanocytes results in patchy or rarely complete depigmentation.  The 
average age of onset is 20 years although vitiligo may appear in 
childhood.  Several hypotheses have been proposed to explain the 
aetiology of vitiligo, including autoimmune, hereditary, neural, 
biochemical (including oxidative stress), and environmental, which may 
interact to contribute to its development. 
Vitiligo was the first disease to be treated by psoralen 
photochemotherapy in ancient Egypt and India. The mechanism by 
which PUVA induces repigmentation remains speculative.  There may 
be an immunomodulatory response suppressing the stimulus for 
melanocyte destruction as well as promotion of melanocyte division.  
PUVA had been considered the gold-standard treatment for vitiligo until 
recently.    
Patient selection and counseling are extremely important. Oral PUVA 
may be considered suitable for patients with extensive disease.  For 
patients with smaller lesions (less than 5% total body surface area), 
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topical 8-MOP is preferred.  However, results are variable. The total 
number of treatments required is between 50 and 300 for extensive 
disease. A complete course of treatment for segmental vitiligo, on 
average, requires 150 treatments.  If there is no response after 4-5 
months (approximately 30-40 treatments) treatment should be 
discontinued.   
Complete repigmentation is achieved in only a few patients. Patients 
with darker skin types appear to show better responses to PUVA.  
Furthermore, repigmented areas may remain stable for  decades. 
However, if therapy is discontinued, partial repigmentation may 
reverse118. A 10-year retrospective study involving 97 patients found 
this treatment to be moderately effective in widespread vitiligo. There 
was a high relapse rate within a year of discontinuing therapy.  Younger 
patients tended to retain their pigmentation longer than older 
patients.119 
Khellin, a furanochromone extracted from the plant Ammi visnaga, is 
structurally similar to 8-MOP, and possesses similar photochemical and 
phototherapeutic properties.  It has been used, both topically and orally, 
in conjunction with UVA (KUVA) in the treatment of vitiligo.  The major 
advantage of khellin is its lack of phototoxicity.  However, approximately 
30% of vitiligo patients receiving oral khellin developed reversible 
increases in hepatic transaminases for unknown reasons presumably 
from the khellin.120  
CHAPTER ONE 
Introduction 
43 
 
 
 
  
 
 
 
 
Figure 1.4: Comparing Structure of Khellin and 8-MOP 
Topical khellin 4% ointment has been applied to vitiliginous skin 20 
minutes before UVA or sun exposure.  Although there were fewer side-
effects compared with topical PUVA, topical khellin was less 
effective.121 
There is growing evidence that nbUVB may be superior to PUVA for 
treatment of vitiligo.  In 1997, Westerhof et al. compared 311-nm UVB 
and topical PUVA for the treatment of vitiligo.  28 patients were treated 
with topical PUVA for 4 months and 78 patients received 311-nm UVB 
for 4 months. Repigmentation rates were 46% and 67% for PUVA and 
UVB respectively.122  The first bilateral comparison study comparing 
nbUVB to PUVA in 15 adult patients showed no significant difference in 
clinical response after 60 sessions123. Parsad et al. published their 
retrospective comparison of 38 patients on oral PUVA and 31 patients 
 
 
Khellin 8 - MOP 
CHAPTER ONE 
Introduction 
44 
 
on NBUVB.  Their results showed a significantly better outcome for   
NBUVB124. Fifty non-segmental vitiligo patients were randomly allocated 
to thrice weekly treatment with nbUVB and oral TMP-UVA in an open 
prospective study.  Although the mean treatment duration was longer 
for nbUVB (6.3 months) than oral TMP UVA (5.6 months), nbUVB was 
found to achieve superior results regarding efficacy and stability125.  
Yones et al. conducted the first randomised, double-blind trial 
comparing efficacy of nbUVB vs. oral 8-MOP (or 5-MOP) UVA in 50 
patients with non-segmental vitiligo.  Treatment was given twice weekly 
and patients were assessed after every 16 sessions. At the end of the 
study, the PUVA group had received a mean of 47 treatments.  Patients 
in the nbUVB group received 97 treatments.  Results showed that 64% 
of patients in the nbUVB group experienced >50% improvement 
compared with 36% of patients in the PUVA group. The colour match of 
repigmented skin was also excellent in all patients treated with nbUVB 
but in only 44% of those treated with PUVA. The authors concluded that 
nbUVB is superior to oral PUVA126. 
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Table 1.4 Studies on Vitiligo comparing nbUVB Vs PUVA 
Author Year No. Patients Findings 
1997 Westerhoff et 
al. 
116 – Extensive 
Vitiligo 
4 months topical PUVA (n=28) vs. 4 months 311nm 
UVB; Repigmentation rates 46% PUVA; 67% 311nm  
UVB   
2006 El Mofty et al. 15  Bilateral comparison study nbUVB vs. PUVA;    No 
significant difference between treatment modalities.  
2006 Parsad et al 69 Oral PUVA (n=38),  nbUVB (n=31);                     
nbUVB significantly better results 
2007 Bhatnagar et al. 50 Open prospective trial;                                           
Thrice weekly nbUVB vs. Oral TMP-UVA; nbUVB 
superior efficacy and stability 
2007 Yones et al. 50 Double-blind Randomised Control Trial;                
Twice weekly Oral 8-MOP (or 5-MOP) vs. nbUVB.   
36% patients PUVA group and 64% patients in nbUVB 
group showed >50% improvement. Repigmentation in 
nbUVB closer colour match than PUVA. 
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Generalised Lichen Planus 
Lichen planus (LP) is a chronic inflammatory idiopathic condition that 
manifests as a pruritic papulosquamous disease.  In most cases of LP, 
disease severity is mild and treatment is limited to topical therapy 
(superpotent corticosteroids).  Severe cases may have greater disability 
requiring more aggressive therapy such as oral steroids. nbUVB, 
acitretin or PUVA.  
Gonzalez et al. treated 10 patients with oral 8-MOP PUVA in a bilateral 
comparison study.  Five patients cleared completely and did not require 
further treatment during the 4-year follow-up. Three patients improved 
by at least 50%, however 2 patients experienced disease exacerbation 
on the treated side.  Maintenance treatments may not be required once 
remission is attained127.  Helander et al. found bath PUVA to be 
superior to oral PUVA.  13 patients received bath PUVA, 10 patients 
had oral PUVA. Good or excellent clearing occurred in 10 (77%) 
patients following eight to forty-six treatments with bath PUVA.  Only 5 
(50%) patients maintained similar results after eight to thirty treatments 
with oral PUVA. Early relapses occurred with both regimens128.  
Combined RePUVA regimen may accelerate clearance of generalised 
and hyperkeratotic forms of lichen planus.   
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Cutaneous Graft versus Host Disease (GVHD) 
Acute and chronic graft-versus-host disease (GVHD), are multisystem 
disorders that occur following allogeneic bone marrow transplantation.  
The skin, liver and gastrointestinal system may individually or 
collectively be affected.  There are 2 forms of this condition: acute and 
chronic.  Acute GVHD occurs within 1 – 3 weeks after transplantation.  
This typically presents as a maculopapular rash which may progress to 
erythroderma.  Chronic GVHD occurs in 30% to 70% of adults and 
children surviving more than 100 days post transplantation and 
presents as a mucocutaneous lichenoid and/or sclerodermatous 
disease. 129,130  
PUVA was initially evaluated for lichenoid GVHD due to clinical and 
histological similarities with lichen planus131. Beneficial effects were 
observed in patients who were non-responsive to conventional 
immunosuppressive therapies. Unlike other conditions, PUVA may 
exert systemic effects. Improvement of mucosal erosions has been 
observed during treatment of chronic lichenoid GVHD.  However the 
results of PUVA treatment for sclerodermoid GVHD are controversial.   
PUVA has also been used in acute GVHD.  Reinauer et al. treated six 
acute cutaneous GVHD grade II III (n=2 grade II, n=4 grade III) patients 
with PUVA.   All patients improved markedly after 5-12 sessions of 
irradiation. 5 patients had complete resolution of skin disease with 8-18 
treatments. Following clearance of acute cutaneous GVHD, 2 patients 
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developed chronic GVHD after therapy-free intervals of 3 and 12 
months, respectively. PUVA confers a protective effect against chronic 
GVHD132.  Oral 8-MOP PUVA has also been successfully used to 
manage severe erythrodermic acute GVHD, in a 34 year-old male due 
to myeloid leukaemia.133 
Prurigo Nodularis / Pruritus 
Prurigo nodularis is an intensely pruritic condition characterised by 
multiple papules/nodules occurring on extensor aspects of limbs and 
the trunk.  The cause is unknown.  Topical antipruritic agents including 
menthol or the use of potent topical corticosteroids (under occlusion) 
are often inadequate.  
The antipruritic effect of UV light appears to be effective in the 
management of this chronic inflammatory skin disease. Fifteen patients 
with prurigo nodularis reported a dramatic improvement of their itching 
within 4 – 6 days following treatment with trioxsalen baths and UVA134.  
Hans et al. treated two patients with thrice weekly UVB to a maximum 
of 30 treatments.  Residual lesions were treated with intralesional 
corticosteroids and topical PUVA135.  However, patients frequently 
relapse following short-term treatment.  Hammes et al. found the 
combination of UVB 308nm excimer light and bath PUVA to be an 
effective treatment modality.  22 patients were included in their 
prospective study.  They received either PUVA alone or in combination 
with excimer UVB. Patients were followed-up four weeks after 
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completion of treatment. The cumulative PUVA-only dose was greater 
(23.7 ± 4.5 J/cm2) than the combination group (16.9 ± 2.7 J/cm2).  One 
patient remained in remission in both groups; however, all patients 
showed a long-term benefit with a notable reduction of itching136.  
Urticaria Pigmentosa 
Urticaria pigmentosa is one of the most common forms of mastocytosis, 
due to an excessive accumulation of mast cells in the skin of uncertain 
cause. Multiple organs (including the bone marrow, spleen, lymph 
nodes, gut, lungs and bone) may also be involved.  
The disease is more common in children than in adults.  The exact 
incidence is unknown.  About 75% of cases occur during infancy or 
early childhood. Incidence peaks again in mid-adulthood (30 to 49 
years).  Adults are more likely to develop systemic disease.137  The skin 
lesions are characterised by brown macules or papules that urticate 
when rubbed (Darier‘s sign). 
Oral PUVA may be an effective long-term treatment of urticaria 
pigmentosa as well as systemic mastocytosis.  Godt et al. 138 
investigated the long-term efficacy of oral PUVA treatment and bath 
PUVA in urticaria pigmentosa and systemic mastocytosis.  Twenty 
patients treated by oral PUVA and four patients treated by bath PUVA, 
were examined retrospectively for a period of up to 18 years. 70% of 
patients treated with oral PUVA therapy showed an improvement.  
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Remission rates ranged from a few weeks to more than 10 years. 25% 
of the patients showed an improvement for more than five years. There 
was no difference in the response rate between urticaria pigmentosa 
and systemic mastocytosis nor was there a correlation with the total 
PUVA dosage.  Younger patients (children and early adolescents) with 
skin types I and II responded better to treatment. Bath PUVA however 
was ineffective138.  
 
Other   
Generalised Granuloma Annulare 
Granuloma annulare (GA) is an idiopathic disorder with several clinical 
variants, of which generalised GA is one. Generalised GA tends to be 
seen in older patients and is characterised by numerous (>10) flesh-
coloured or erythematous papules.  The histological hallmark is 
necrobiosis surrounded by a lymphohistiocytic infiltrate. 
There have been reports of complete clearance of generalised GA 
following PUVA139 however, long-term maintenance treatment on a 
weekly or twice monthly basis was required to maintain remission. 
Browne et al.140 conducted a retrospective study of 33 patients with 
generalised GA over 13 years (1995 – 2008). Patients were treated 
twice weekly with oral 8-MOP PUVA (38 treatments), while bath PUVA 
was used in six treatments. Patients who were intolerant of oral 8-MOP 
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received 5-MOP. The maximum dose of UVA administered was 
12 J/cm2. Although, there was a good initial response, the majority 
(68%) relapsed within 2 years.140 
 
Localised Sceroderma 
Localised Scleroderma (LS), also known as morphoea, is a chronic, 
localised hardening and thickening of the skin. Lesions are categorised 
according to their appearance: morphoea (guttate, profunda, 
pansclerotic) or linear (with/without melorheostosis or hemiatrophy). 
There is a female:male preponderance 2:1. Characteristic features 
include skin ischaemia, lymphocytic infiltrates, swollen collagen 
bundles, and thickening of the dermis with reduction of subcutaneous 
fat. 
 Localised scleroderma and pansclerotic morphoea have both been 
successfully treated with bath PUVA and oral PUVA. In 1994, Kerscher 
et al. reported the first two cases of LS treated with bath PUVA.  
Patients received 30 treatments over 10 weeks (maximum single dose 
of 20J/cm2) leading to almost complete clearance of lesional skin.141 
Evaluation of 17 patients receiving bath PUVA, revealed a marked 
improvement in 13 patients who had received 15 treatments142.  The 
maximum dose ranged between 1.2J/cm2 - 3.5J/cm2.  Pasic et al. found 
bath PUVA useful in the treatment of childhood LS143. 
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Pityriasis Lichenoides (acute and chronic) 
Pityriasis lichenoides (PL) is a self-limiting papulosquamous skin 
disease with a spectrum of clinical manifestations.  These range from 
pityriasis lichenoides et varioliformis acuta (PLEVA), characterised by 
rapid development of necrotic lesions associated with fever and 
systemic involvement, to pityriasis lichenoides chronica (PLC), a 
chronic relapsing variant.  There are also overlapping forms of the 
condition.  Phototherapy has commonly been employed in the treatment 
of patients with PL. 
Fifteen patients were randomised to receive either oral 8-MOP PUVA (8 
patients) or nbUVB (7 patients).  Patients receiving nbUVB had 200 mJ 
⁄m2 initially and then three times weekly. The dose was increased by 
10% at each visit.  For PUVA, doses for patients with Fitzpatrick skin 
type I-III was 1–1.5 J ⁄m2 and 2 J ⁄m2 for patients with skin type IV–V. 
The dose increment was 2 J ⁄m2 every two sessions. Results were 
equivocal in bothgroups, 87.5% patients treated with nbUVB and 71.4% 
patients treated with PUVA showed good response.144 
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Lymphomatoid Papulosis 
Lymphomatoid papulosis (LyP) is part of a spectrum of CD30 (Ki-1)–
positive cutaneous lymphoproliferative diseases.  Histologically, LyP 
has features suggestive of a malignant lymphoma.  However, there is 
on-going debate whether to classify this chronic papulonecrotic or 
papulonodular skin disease as a true malignancy due to its 
spontaneous resolution and benign clinical course. 
Experience with PUVA is limited to a small case series. 5 patients with 
lymphomatoid papulosis were treated with PUVA. 4 patients had 
classical lymphomatoid papulosis; the other patient had 1-2 cm 
tumours. Doses ranged between 51-124 J/cm2 for the patients with 
classical lymphomatoid papulosis, whereas the patient with tumours 
received 481 J/cm2.  The total number and life-cycle of the lesions 
decreased in all patients.  One patient, who had the disease for one 
year prior to PUVA treatment, entered complete remission whilst the 
remaining patients had partial remissions.  The authors suggested that 
early treatment equated to a better response. However, there was no 
subsequent follow-up data to comment on long-term prognosis145. 
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Langerhans Cell Histiocytosis 
Langerhans cell histiocytosis (LCH) is a rare disease characterised by 
clonal proliferation of Langerhans cells and cytokine over-production. 
This results in inflammation and tissue destruction.  LCH may affect a 
single or multiple organ systems.  Commonly involved sites include 
bone, skin, lung, reticulo-endothelial system and other organs.  
Treatment is dependent on the organ(s) affected and severity of 
disease. LCH may occur at any age. 
A 32 year-old Caucasian female with generalised eruptive histiocytoma 
(GEH) was treated with systemic PUVA. Following 20 treatments, the 
skin lesions completely resolved with no relapses146. A 23-year-old man 
with LCH was treated with oral 8-MOP PUVA three times weekly for two 
months and then once or twice with maintenance phototherapy. There 
was no recurrence of lesions during the four-month follow-up period.147 
A 74-year old male with LCH skin disease was successfully treated with 
PUVA.148  
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Purpuric Pigmented Dermatoses 
Pigmented purpuric dermatoses (PPD) are a group of chronic recurring 
disorders of unknown aetiology.  They are characterised by purpuric 
lesions mainly involving the lower extremities. 
Treatment of this condition is generally unsatisfactory.  There have 
been case reports of successful treatment following PUVA therapy, with 
patients being maintained in remission. Krizsa et.al managed seven 
patients who had pigmented purpuric lichenoid dermatosis (Gougerot-
Blum) with PUVA. All patients cleared after seven to twenty treatments. 
The cumulative dose of UVA dose ranged between 16–49 J/cm2. 5 
patients remained in remission (7 - 76 months). Two relapsing patients 
responded to a second course of PUVA therapy. Similar outcomes were 
reported in another series involving eleven PPD patients (five had 
Schamberg's disease, five had Gougerot-Blum and one had eczema-
like purpura of Doucas and Kapetanakis) 149,150,151 
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Pityriasis Rubra Pilaris 
Pityriasis Rubra Pilaris (PRP) is an uncommon group of 
papulosquamous skin diseases of which there are 6 types.  The most 
common is the adult classical type (type I).  This is characterised by 
follicular keratoses, palmoplantar keratoderma and abrupt onset of 
erythroderma with islands of sparing of normal skin.  
There is inconsistency regarding results of PUVA as a treatment 
modality for PRP.  Some patients have successfully been treated with 
bath PUVA whilst others may flare requiring treatments with 
methotrexate or retinoids. 152,153 
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Induction of tolerance in photosensitivity disorders 
Polymorphic Light Eruption (PLE) 
PLE is the most common photodermatoses and develops within hours 
and may persist for days following exposure to sunlight. However, with 
repeated exposures to sunlight, the tendency to develop PLE in most 
patients diminishes with time by a phenomenon known as hardening 
(tolerance).  
PUVA and UVB were compared in a double-blind trial involving 42 
patients between April-September 1983. Patients were randomly 
allocated to three groups, PUVA (with oral 8-MOP), UVB with oral 
placebo, and control low-dose UVA with oral placebo. The treatment 
groups commenced treatment with a third of the predetermined MPD or 
MED.  Patients received thrice weekly treatments for six weeks.  At 
each visit, doses incremented by an eighth in the PUVA group and by a 
seventh in the UVB group. Patients‘ were followed-up at 4months.  
PUVA appeared to be more effective than UVB from patient‘s subjective 
reports.154 
Narrow-band UVB was compared with oral PUVA in 25 patients thrice 
weekly for five weeks in the spring.  There was no significant difference 
between treatment groups. 85% of patients in each treatment group 
were adequately protected from developing PLE in the summer.  
CHAPTER ONE 
Introduction 
58 
 
However, nbUVB may be a more convenient effective treatment for 
PLE.155 
Solar Urticaria 
Solar urticaria is a rare form of urticaria occuring within minutes of 
exposure to sunlight or an artificial light source emitting the appropriate 
wavelength. 
If antihistamines are ineffective then PUVA is indicated.  However, pre-
PUVA desensitization with UVA is often necessary as patients have 
been reported to flare with PUVA156.  Alternatively, PUVA treatment 
may be fractionated, with small doses of UVA (0·1–0·25 J/cm2, for 
example) given every 15 minutes, starting 1 hour after psoralen 
ingestion. The result is a therapeutically useful cumulative dose, yet 
individual exposures remain below the threshold required to trigger 
urticaria.157   
Omalizumab, an anti-IgE antibody approved for use in chronic 
spontaneous urticaria, has also been used in solar urticaria with 
variable results.  A 24-year-old patient with solar urticaria received four 
doses of Omalizumab 150mg subcutaneously at four weekly intervals 
but had no demonstrable changes in phototesting at the end of the brief 
study.158  Three cases of solar urticaria were reported to have been 
successfully treated with Omalizumab at differing doses.159 Further 
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studies are required to investigate the optimal dose and injection 
interval for such patients. 
 
Chronic Actinic Dermatitis 
Chronic actinic dermatitis (CAD) is a condition mainly affecting men 
over the age of 50 years. It is intensely pruritic and is characterised by 
inflamed, erythematous, thickened eczematous skin, mainly occurring in 
sun-exposed areas.  Some patients also react to artificial light sources. 
Patients may have co-existing contact allergic dermatitis, particularly to 
plants or photo-contact dermatitis for many years before the sensitivity 
develops.  Occasionally, CAD occurs as a persistent eczematous rash 
following withdrawal of a photosensitizing drug.   
Four male patients with severe CAD were treated twice weekly with 
PUVA.  The starting dose of UVA was 0.25J/cm2 with increments of 
0.25J/cm2 to 1J/cm2.  The maximum dose was 10J/cm2.  Topical 
steroids were applied to the rest of the body immediately after the first 
six treatments.  All patients responded very well and were maintained 
on twice monthly PUVA therapy (10 J/cm2).160   
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Hydroa Vacciniforme (HV) 
Hydroa vacciniforme is a very rare, idiopathic photodermatosis 
occurring in childhood.  Patients develop recurrent crops of 
papulovesicles or vesicles on sun-exposed skin that heal with 
characteristic varioliform scarring. One male patient received PUVA 
therapy with good control of his disease.161 However, in a review of 10 
cases, there was a flare of HV in the one patient treated with PUVA 
whereas there was improvement in two patients who were treated with 
UVB.162 
 
Erythropoietic Protoporphyria 
Erythropoietic Protoporphyria (EPP) is a non-acute porphyria due to 
deficiency in ferrochelatase, the final enzyme in haem biosynthesis.  
This results in the accumulation of protoporphyrin, the two principal 
manifestations of which are: acute cutaneous photosensitivity typically 
occuring in childhood and hepatobiliary disease. Although nbUVB, has 
been shown to be an effective preventative treatment for 
photodermatoses and is more commonly prescribed, PUVA may also 
increase sun tolerance.163
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Minimal phototoxic dose (MPD) measurements 
for topical photochemotherapy using a 
semiautomated MPD tester 
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2.1 Background 
Psoralen–ultraviolet A (PUVA) phototherapy has an important 
therapeutic role in cases of dermatoses recalcitrant to conventional 
narrowband UVB phototherapy, and is still used particularly in psoriasis, 
atopic eczema and mycosis fungoides.80  Initial treatment doses are 
limited by the sensitivity of unaffected, normal skin. To optimise PUVA 
phototherapy, it is important to establish the lowest dose of UV radiation 
that causes a just perceptible erythema – the minimal phototoxic dose 
(MPD). This enables determination of  a safe initial dose.  
Recommended start doses are 40% of this MPD. 
 The British Photodermatology Group guidelines52  also recommend 
subsequent dose increments based on a percentage (20 – 40%) of the 
previous dose. The MPD also establishes that sufficient psoralen is 
present in the patient‘s skin. If the extent of disease is so widespread as 
to preclude MPD testing, the initial dose is based on skin phototype.   
The traditional method of assessing MPD is cumbersome and time 
consuming for both patients and staff and requires a separate source of 
UVA.  It involves applying UVA light to skin sensitised with psoralen via 
eight square apertures through a panel of UVA lamps. A typical patient 
with psoralen-sensitised skin is required to be seated 20cm from the 
panel of UVA lamps. The template consisting of 8 square apertures is 
put on to the patient‘s lower back and the remainder of the patient‘s skin 
is covered to protect from UVA light. Seven of the 8 apertures are 
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covered with dense removable tape. Each one of the apertures is 
exposed at a specific time to deliver the appropriate dose of UVA. A 
timer is set to the maximum time required to deliver the dose sequence 
(see below) and initiated concurrently with the UVA panel irradiation.  
 
 
Figure 2.1 MPD Template
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Figure 2.2 Template on Back, protection of surrounding skin 
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Figure 2.3 Patient sitting 20cm from UVA lamps 
The dose sequence comprises of the maximum dose as determined by 
the protocol, with a factor of square root of 2 (1.41) between adjoining 
areas.  Each dose is set in a table with the time requirements to deliver 
that dose at 20 cm distance from the face of the calibrated output from 
the UVA panel.  
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A typical dose sequence is shown below: 
2.2 J/cm2, 1.55 J/cm2, 1.10 J/cm2, 0.78 J/cm2, 0.55 J/cm2, 0.39 J/cm2, 
0.28 J/cm2 and 0.20 J/cm2.  
 
 In our unit, this would  take 15 - 20 minutes.  This ‗open‘ source Is 
associated with the potential for errors, including UV source non-
uniformity due to curvature of the test site, patient movement and 
exposure timing errors.  The difficulties (due to time required, 
equipment and training) of performing MPD testing discourage its 
widespread adoption.  We are interested in establishing how many 
phototherapy centres use MPD testing prior to a course of topical 
PUVA. An easier, safer method of establishing the MPD may 
encourage more centres to perform this check.  A device that 
overcomes many of these difficulties is the minimal erythema dose 
(MED) tester used for UVB.164 This uses a compact fluorescent lamp 
(CFL) in a handheld housing as the source and a UVB opaque template 
with 10 x 1-cm-diameter apertures. The output of nine of these 
apertures is successively attenuated by a factor of 3√2 by steel shaver-
type foils. Our previous study established that the test–retest reliability 
of this method was high.164 The kappa measure of agreement was 
calculated for the comparison of two MED tests prepared on the same 
patient at the same time, and for two MED tests on the same patient but 
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administered 24 h later. Both scenarios gave agreement of 0.8 or 
higher, indicating excellent agreement. 
 
 
 
 
 
Figure 2.4 Modified Hand-Held Tester 
Differences in photosensitivity responses to the same UV dose 
administered using different magnitudes of irradiance (testing 
‗reciprocity‘) have been checked by our group using a high-intensity 
UVA-1 light-emitting diode source. We found no differences in MED 
using 100mW/cm2 and 200 mW/cm2 intensities. This indicates that 
there are unlikely to be significant differences between our two MPD 
methods, which differed in applied UVA-1 irradiance by a factor of 2 
(approximately 8 mW/cm2 for PUVA panel vs. approximately 16 
mW/cm2 for a modified UVA MPD tester). 
CFLs with the same UVA spectrum as phototherapy lamps (Philips Cleo 
series lamps; Philips, Amsterdam, The Netherlands) are not available. 
As industrial, consumer and medical users of UVA require larger 
irradiation areas, this has been achieved using traditional 6-foot (180-
cm) and 2-foot (60cm) fluorescent tubes. Manufacturers have little 
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commercial incentive to choose UVA CFL spectra that are exactly the 
same as those of the larger tube lamps. The nearest equivalent CFL to 
a PUVA lamp is the Philips TL-10 CFL, which has a narrower spectrum 
centred around a longer wavelength (370nm). 
As PUVA photochemotherapy uses only psoralen as the sensitiser and 
only PUVA-designated lamps, it should theoretically be possible to 
establish a fixed factor to convert the observed MPD using  the TL-10 
CFL to a PUVA-equivalent MPD for all patients. This would be 
convenient and repeatable, ameliorating many of the disadvantages of 
the traditional method. 
 
2.2 Aims 
1. To assess the results of an MPD measurement technique, using 
a hand-held UVA lamp with a built-in template with varying 
attenuators and compare these to those from the standard 
method of MPD determination using an open UVA light box as the 
source of UVA. 
2. To calculate a fixed factor to convert the observed MPD with the 
handheld device to a PUVA-equivalent MPD. 
3. To assess routine practice concerning MPD testing prior to PUVA 
therapy in UK phototherapy units. 
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2.3 Design of the Study 
This was a randomised, left-right comparison study within patients.  
Patients with psoriasis referred to the phototherapy unit for PUVA 
treatment at St. Woolos Hospital, Newport were recruited for this study. 
 
2.4 Ethical Approval 
Before commencement of this study, ethical approval was obtained 
from the South East Wales Local Research Ethics Committee.  
Approval was also sought and obtained from the Aneurin Bevan 
Healthcare NHS Trust Scrutiny and Risk Review Committee. (Ref No. 
05/WSE03/168)  
 
2.5 Written Informed Consent 
An information sheet describing the study and procedures to be 
performed was supplied to each patient prior to their starting the study.  
The study was fully explained and patients were then required to 
provide their written, witnessed consent.  A copy of the information 
sheet and consent form is included in appendix I.  
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2.6 Study Subjects 
A minimum of 30 patients, at least 18 years old referred to the 
phototherapy unit at St Woolos Hospital for PUVA treatment were 
selected.  Patients were pre-treated with topical psoralen soaking 
before exposure to UVA. 
2.61 Inclusion criteria 
1. Aged at least 18 years. 
2. No recent sun exposure to lower back / upper buttock 
skin. 
3. Has been referred for PUVA treatment 
4. Has signed the consent form after the nature of the study 
has been fully explained. 
2.62 Exclusion criteria 
1. Pregnant or lactating females, or females of reproductive 
potential not using a medically approved form of 
contraception. 
2. Use of medication likely to interfere with the study. 
3. Use of an experimental drug within the previous 30 days. 
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4. History of skin disease or allergy likely to interfere with the 
study. 
5. Unwilling or unable to give written consent. 
6. Recent psoriatic plaque at the site of measurement. 
2.7 Materials and Method 
Dose Range Determination  
The lamp used in the handheld MPD tester (Philips TL10, 370nm) 
differs in its spectrum from the PUVA tubes used for phototherapy 
treatment.  Using the published topical psoralen erythema action 
spectrum of Cripps et al38, the new lamp spectrum can be weighted to 
estimate its erythemal potential in psoralen sensitised skin.  This 
technique is described in more detail in Chapter 3. 
When the psoralen-equivalent erythema action spectrum was 
calculated for the TL10 lamp, the predicted erythemal efficacy would be 
0.15 times the erythemal efficacy of the PUVA lamps.  Dosing 
schedules for the hand-held MPD tester were calculated using this 
factor. 
   A prospective randomised left–right comparison study was carried out 
on 31 patients with psoriasis due to commence topical PUVA 
phototherapy. All patients soaked in 30mL 1·2% 8-methoxypsoralen 
bath lotion (Puvasoralen; Crawford Pharmaceuticals, Knutsford, U.K.), 
in 140L water (2·6mgL−1psoralen) for 10min at 37°C. All patients 
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recruited had a template with 8×1-cm or 10×1-cm square apertures with 
removable covers applied to an uninvolved area of skin of the lower 
back. The remainder of the patient's skin was fully protected from UV 
exposure.  
A panel of UVA lamps, calibrated for UV irradiance, was positioned 
20cm from the patient and was used to illuminate the test site after a 
warm-up period of 10min. The covers on the test sites were removed 
sequentially at specific intervals enabling a graduated decrement of 
UVA dose by a factor of √2 between successive sites. The modified 
handheld MPD tester was used on a symmetrical contralateral site on 
the lower back. A randomisation table was produced using the random 
number function in Microsoft Excel to determine the method of MPD 
testing, i.e. ―hand-held‖ MPD tester versus panel of PUVA lamps, to 
either right or left side of lower back. Precise positioning of each test 
was further influenced by the extent and position of the uninvolved skin 
on that side of the lower back. 
The modified handheld MPD tester was calibrated for UV output using a 
Bentham DM150 spectroradiometer.  The DM150 was calibrated 
against a tungsten lamp which had a calibration from 250nm – 800nm 
traceable to the National Physical Laboratory. For a calibration with a 
margin of 8% uncertainty, the compact MPD tester requires a two 
minute warm-up and 15 minute cool-down between successive MPD 
tests. MPD test results from a panel of PUVA lamps were compared 
with the MPD from the modified Durham MPD tester (10 apertures with 
CHAPTER TWO 
 
73 
 
1·26 factor between doses). Erythema was assessed 96h later (bath 
PUVA). Phototherapy nurses assessed MPD reactions according to 
usual practice. They were not blinded to the test method allocation.  
Blinding of the assessors was not possible due to the visible 
characteristic pattern of MPD erythema from the two methods. The 
hand-held tester was manufactured with circular apertures, whereas the 
‗homemade‘ template used square cuts in the self adhesive plastic 
template. Also, it would have been very difficult to reproduce the tight 
spacing of the manufactured aperture plate of the Durham tester in 
adhesive backed plastic. 
 
A questionnaire survey was sent to 78 phototherapy units around the 
U.K. to gauge current practice concerning usage of MPD testing in 
phototherapy treatment protocols. Responses from 43 phototherapy 
units were obtained. The survey comprised five questions including the 
following: 
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1. Which hospital(s) are you based at? 
2. Does your department provide a phototherapy service? 
Yes  
No  
3. Do you offer: 
(whole-body) Bath PUVA 
(localised) Hand/Foot PUVA  
Systemic PUVA 
4a. Do you routinely assess Minimal Phototoxic Dose (MPD) prior to 
PUVA phototherapy? 
  Yes   
  No          ( go to 4b) 
4b. Is this because (please circle as appropriate): 
i) Treatment is commenced based on Fitzpatrick skin type 
ii) MPD assessment is time-consuming 
iii) MPD assessment is inconvenient 
5. When treating patients with localised topical PUVA (hand/foot) do 
you: 
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a) dry the area and irradiate immediately with UVA following immersion 
in psoralen 
b) dry the area and wait 30 mins after immersion in psoralen before 
irradiating with UVA 
c) other (please specify)  
 It was estimated that accurate completion of the questionnaire would 
take no more than 3 minutes. 
2.8 Results 
Thirty-seven patients with psoriasis (17 women and 20 men) aged 18–
65years were recruited. Six had inconclusive MPD reactions and were 
excluded from the studies. This meant that the patient did not have two 
comparable MPD reactions, only one MPD was visible.  In the first 
patients tested the dose range applied with the modified Durham tester 
was based on the expected erythemal reaction calculated using the 
data from Cripps. Some of these applied dose ranges did not elicit an 
erythemal reaction. For subsequent patients the applied dose range 
was increased. In other patients the reaction was not present on the 
handmade template sites. This could have been because of the 
inherent variability in patient positioning using the older method, or 
because the patient had been assigned a skin phototype which did not 
accurately reflect their true psoralen-sensitised skin photosensitivity. 
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The phototypes of the remaining 31 patients included: 
 
Table 2.1 Phototypes of 31 patients 
 
Skin Phototype Number of Patients 
I 4 
II 11 
III 12 
IV 4 
  
 
Linear regression was performed on logarithmically transformed data, 
as a geometric dose series was used, as shown in figure 2.5 
The handheld MPD results were linearly related to the PUVA panel 
MPD results as follows: 
 
PUVA MPD =  0.48 x handheld tester + 0.17 J/cm2 
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The measured PUVA MPD was 0·48 times the handheld MPD, not 0·15 
as predicted by the published PUVA action spectrum. The ratios of the 
PUVA MPD to the handheld MPD ranged from 0·43 to 1·08. The PUVA-
equivalent MPD differed by a maximum of 0·28Jcm−2higher and 
0·26Jcm−2lower than the panel MPD; in 90% of cases the difference 
was one or fewer MPD categories.  
The results of our survey revealed that only six of 43 phototherapy 
centres (14%) that responded to our survey routinely performed MPD 
testing. The remainder found the practice was time consuming, and 
commenced treatment based on Fitzpatrick skin type 
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F
Figure 2.5: Relationship between the logarithmic transformed minimal 
phototoxic dose (MPD) values determined by the handheld MPD tester 
and from a panel of psoralen–ultraviolet A lamps. Pearson's correlation 
coefficient, r = 0·82,P<0·001. Dotted lines represent the 95% 
confidence intervals about the line of best fit. Overlapping data points 
are not shown.   
2.9 Discussion 
The handheld MPD results are linearly related to the PUVA panel MPD 
results. However, the difference in MPD between the PUVA lamp and 
the modified handheld MPD tester (CFL TL-10 lamp) was much less 
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than predicted from the PUVA action spectrum37. The erythemal 
effectiveness of the TL-10 lamp, calculated using the PUVA erythema 
action spectrum of Cripps et al38, is 2·48, compared with the PUVA 
lamp effectiveness of 16·33 (arbitrary units). Thus PUVA MPDs should 
be 0·15 of the TL-10 MPDs. This suggests that formal re-evaluation of 
the erythema action spectrum for PUVA is now needed. We conclude 
that the small handheld MED tester, being convenient and reliable, 
could be made available for MPD testing by replacing the UVB tube 
with a CFL TL-10 tube. The MPD dose is then adjusted according to our 
results to indicate a PUVA-equivalent dose. 
Furthermore, only 14% of phototherapy centres surveyed routinely 
assess MPD prior to photochemotherapy, the principle reason being 
that it is too time consuming. 
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Results of Questionnaire Survey 
 
Figure 2.6 Routine Measurement of MPD prior to PUVA exposure 
 
 
 
 
Figure 2.7 Reasons for Not Performing MPD assessment 
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Erythema Action Spectrum of Topical  
Psoralen-Sensitised Skin Re-evaluated 
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3.1 Background 
Published research on the topical psoralen ultraviolet A (PUVA) 
erythemal action spectrum has used methods that do not reflect current 
clinical practice for psoralen sensitization. The study by Cripps et al.38 
used 8-methoxy psoralen at 1% dissolved in acetone and then in 
ethanol and applied (via pipette) directly to the skin of the lower dorsum 
trunk of 6 Caucasian males.  This was then followed by irradiation with 
various wavelengths of UVA. No details were provided for the time 
between application of psoralen and UVA irradiation.   MPDs were read 
at 72 hours.  Their findings were a peak sensitivity between 330-335nm 
for 8-MOP, 6 times more effective than 365nm.  In the study by Buck et 
al.34 there was a delay of between 1½ - 2 hrs between application of 1% 
8-MOP solution in chloroform and illumination with UVA. 
This scenario differs greatly from present clinical practice in the UK, 
where the skin is immersed in an aqueous solution of 8-
methoxypsoralen at 37ºC39 for 10 minutes, followed by UVA irradiation 
within 30 minutes.  The study by Schempp40et al. showed there was a 
marked, significant reduction in erythema after 60 minutes delay 
between soaking in an 8-MOP bath and irradiation and no erythema 
was detected after 180 and 360 minute delay.   Man et al57 showed that 
time to develop topical 8-MOP induced erythema had a broad peak at 
120 hours. However, MPD assessment during or beyond 120 hours is 
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best avoided due to confounding effects of the development of 
pigmentation.  Their recommendation was that topical 8-MOP MPD 
should be read four days (96 hours) after exposure.52,57  We therefore 
re-evaluated the PUVA erythema action spectrum using aqueous 
psoralen at 2.6mg/L concentration as is used routinely in current clinical 
practice in the UK and assessed MPDs at 96 hours.  We then used our 
action spectrum to estimate the ―PUVA equivalent‖ output of a range of 
UVA sources. 
 
3.2 Aims 
1. To determine a range of the erythema action spectrum of topical 
8-MOP solution between 325nm to 375nm on normal skin under the 
same conditions as used in current clinical practice. 
2. To determine the dose-response characteristics of topical PUVA 
erythema in normal skin. 
4. To establish the relative erythemal efficacy of a range of UVA 
lamps on topical psoralen sensitised skin. 
 
3.3 Design of the Study 
This was a dose-response and dose-ranging study involving 20 healthy 
volunteers.  MPD‘s were established at 6 wavelengths between 325nm 
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and 375nm at 10nm wavelengths (325nm, 335nm, 345nm, 355nm, 
365nm and 375nm).  Three defined wavelengths of UVA (325nm – 
375nm) were tested on each forearm of each subject. Subjective 
assessment of erythema and objective assessment of erythema (using 
an erythema meter, Mexameter MX16, Courage & Khazaka, Cologne, 
Germany) were recorded for each site at 96 hours. 
 
 3.4 Ethical Approval 
Before commencement of this study, ethical approval was obtained 
from the South East Wales Local Research Ethics Committee.  
Approval was also sought and obtained from the Aneurin Bevan 
Healthcare NHS Trust Scrutiny and Risk Review Committee. (Ref No. 
14/WA/0029)  
 
3.5 Written Informed Consent 
An information sheet describing the study and procedures to be 
performed was supplied to each patient prior to starting the study.  The 
study was fully explained and patients were then required to provide 
their written, witnessed consent.  A copy of the information sheet and 
consent form is included in appendix II.  
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3.6 Study Subjects 
Twenty healthy volunteers were recruited.  
3.61 Inclusion criteria 
1. Age range 18 – 65 years. 
2. Normal skin. 
3. No significant illness. 
4. Has signed the consent form after the nature of the study 
has been fully explained. 
3.62 Exclusion criteria 
1. Presence or history of significant skin disease. 
2. Significant concurrent illness likely to interfere with the 
study including malignancy. 
3. Use of medication likely to interfere with the study, 
including immunosuppressant and photosensitising drugs. 
4. Pregnant or lactating females 
5. Unwilling or unable to give written consent. 
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3.7 Method 
Following approval by the South East Wales Local Research Ethics 
Committee, a prospective randomised single-blinded study was carried 
out on 20 healthy volunteers with skin phototypes I-V.  A randomisation 
table was produced using the random number function in Microsoft 
Excel to determine the location of each wavelength to either right or left 
forearm. The position of each wavelength test area was not blinded to 
the assessors. The Boston classification of skin phototype was 
determined in all volunteers.58 Their forearms were soaked in 2.5mL 
1·2% 8-methoxypsoralen bath lotion (Puvasoralen; Crawford 
Pharmaceuticals, Knutsford, U.K.). in 10L water (2·6mgL−1psoralen) for 
10min at 37 C. After drying the area,  a template made from opaque 
Fablon (sticky backed plastic) with 18 holes (6 mm diameter) in a grid 
pattern was applied to the volar forearms 2cm from the antecubital 
fossae to facilitate accurate irradiation of the test sites, and again at the 
time of reading to help identify the previously irradiated sites. UVA 
irradiation was then applied.  Six UVA irradiations at 10nm intervals with 
centre wavelengths between 325nm – 375nm were administered to 
each volunteer‘s volar forearm skin (3 wavelengths per forearm) using a 
1Kw xenon arc irradiation monochromator (components from Newport 
Oriel, USA) with a full width at half maximum (FWHM) bandwidth of 
10nm.  A water filter removed infra-red radiation. A Schott WG320 filter 
was used to reduce the UVB content. The UVB content at each 
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wavelength band was checked from their measured spectra. The 
325nm spectrum contained less than 0.1% UVB, while all other 
wavebands used contained less than 0.01% UVB 
For each volunteer at each wavelength the irradiance at the application 
face of the light guide was measured using a calibrated radiometer.  
This was used to calculate the times (minutes:seconds)  required to 
apply the dose sequence for that wavelength to the volunteer‘s skin.   
 
Figure 3.1 Templates on volunteer‘s forearms 
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Measured irradiances at each centre wavelength ranged as follows:  
Table 3.1 Measured Irradiance for each wavelength 
Centre Wavelength (nm) Irradiance (mW/cm2) 
325 24.2 – 36.6  
335 33.6 – 49.6  
345 39.8 – 59.5 
355 48.9 – 66.6  
365 52.5 – 71.8  
375 58.0 – 75.2 
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Figure 3.2 Application of dose sequence for wavelength
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Each site was irradiated with a sequence of geometrically increasing 
(40% increment) doses via a liquid light guide with a circular area of 
5mm diameter.  Erythema was measured using an erythema/melanin 
meter (Mexameter, Courage and Khazaka) at each of the 6 sites.  One 
measurement of non-irradiated skin at each of the 6 sites was also 
recorded.  Visual assessments of erythema were recorded agreed by 2 
observers and recorded for each site at 96 hours. At each wavelength 
the dose required to elicit a barely perceptible erythema was designated 
as the MPD for that particular wavelength. 
 
3.8 Results 
Boston phototypes in the 20 volunteers (14 females, 6 males) with 
mean age 44.5 years (range: 23-67years) were as follows: 
 Type I; two;  
Type II; six;  
Type III; six;  
Type IV; five  
Type V; one. 
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The mean MPD (J/cm2) for all subjects at each wavelength was as 
follows: 
325nm-0.64(SD 0.37); (0.27 – 1.77)  
335nm–0.80(SD 0.58); (0.27 – 2.5) 
345nm–0.96(SD 0.55); (0.35 – 2.5) 
355nm–1.50(SD 0.85); (0.44 – 3.2) 
365nm–2.19(SD 0.90); (0.53 – 4.5) 
375nm–2.89(SD 1.06). (0.53 – 4.5) 
 
 CHAPTER THREE 
92 
 
Figure 3.3: Minimal Phototoxic Dose (MPD) of all volunteers at each 
wavelength 
PUVA erythemal effectiveness was determined by wavelengths 
(ANOVA p<0.05).  
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There were no significant differences between the PUVA erythema 
action spectrum and skin types. 
                                           
 
Figure 3.4: MPD by Skin type at each wavelength 
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Figure 3.5: MPD at each wavelength in a volunteer 
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The mean MPD values can be used to calculate the relative 
sensitisation at each wavelength (the erythemal action spectrum). The 
action spectrum for topical PUVA erythema at 10nm intervals between 
325nm and 375nm was: 1, 0.8, 0.67, 0.43, 0.29, and 0.22. Using 
Microsoft Excel at linear least squares best fit was applied to these 
values. The best fit equation was: 
 
y = -0.0162x + 6.2383    R² = 0.98  
 
 
The equation was used to interpolate values of the action spectrum at 
1nm intervals between 320nm and 400nm. All calculated values of the 
action spectrum were constrained to lie between 0 and 1, since values 
outside these limits are not possible. 
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Figure 3.6: Topical PUVA Erythema Action Spectrum 
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Table 3.2 Action Spectrum at 5nm Intervals 
Wavelength(nm) Relative Erythema Action Spectrum Topical PUVA 
320 1.00 
325 1.00 
330 0.90 
335 0.80 
340 0.72(5) 
345 0.67 
350 0.57 
355 0.43 
360 0.40 
365 0.29 
370 0.25 
375 0.22 
380 0.10 
385 0.02(5) 
390 0 
395 0 
400 0 
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Discussion 
It has been shown that the action spectrum of oral 8-MOP PUVA for 
clearance of psoriasis follows the PUVA erythema action spectrum165.  
If we realistically assume that this will also be the case for topical 
PUVA, this topical PUVA action spectrum can be used to assess the 
relative efficacy, or efficiency, of any lamps used for topical PUVA 
phototherapy. For example, typical fluorescent lamps that are used for 
whole-body and extremities PUVA can be compared to newer UVA 
sources.  
Applying the PUVA erythema action spectrum relative sensitivities at  
each wavelength to those measured in any UVA lamp spectrum allows 
the calculation of the ―PUVA equivalent‖ output from that lamp. The 
ratio of PUVA equivalent outputs between any two UVA lamps can be 
used to describe the ―PUVA efficiencies‖ of one lamp compared to 
another. Table 3.3 shows the PUVA effective ratio of typical PUVA 
sources used in clinical practice and other UVA lamps that may also be 
used for PUVA phototherapy. 
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Lamp Irradiance / PUVA erythemal 
irradiance 
PUVA 
effective 
ratio 
UV800K 2-ft fluorescent lamp 2.145/4.465 0.48 
Philips Cleo PUVA 6-ft fluorescent 
lamp 
7.43/16.29 0.456 
UVA1 LED 0.754/6.23 0.12 
Blacklight compact fluorescent lamp 1.196/2.565 0.466 
PhilipsTL10 compact fluorescent 
lamp 
3.929/16.62 0.236 
PUVA 180 UVA compact 
fluorescent lamp 
2.956/7.461 0.396 
TP4 UVA compact fluorescent lamp 10.64/22.25 0.478 
Enfis UNO light engine 365nm LED 12.44/55.93 0.22 
 
In a previous study166 we used the action spectrum published by Cripps 
et al.38  to predict the PUVA erythemal efficacy of a Philips TL10 UVA1 
compact fluorescent tube lamp compared to our standard PUVA lamps 
used to establish the MPD of patients in our phototherapy unit. We 
predicted that the TL-10 lamp should be 0.15 as effective as the PUVA 
Table 3.3 PUVA effective ratio of typical PUVA sources used in clinical practice. 
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lamp. However, when we performed MPD assessments using each of 
these lamps in 37 of our patients we found that the TL-10 lamp was in 
fact 0.48 as effective. We concluded that the published action spectrum 
was unreliable, and should be re-assessed. We can now examine the 
effectiveness of these same lamps calculated using the action spectrum 
we have established in this study. The table gives PUVA efficiency of 
the 2-ft fluorescent tube as 0.48, and that of the TL-10 UVA1 CFL lamp 
as 0.236. The ratio of these gives our prediction of the relative 
erythemal efficacy of the UVA1 lamp compared to the PUVA lamp. This 
value (0.236/0.48) is 0.49, which is almost exactly the value (0.48) that 
we measured from the MPD results from our volunteer patients. This 
gives strong evidence of the validity of the action spectrum measured in 
this study.  
The therapeutic action spectrum of 8-MOP differs markedly from its 
absorption spectrum.31   Potential reasons for this are psoralen and 8-
MOP, undergo chemical changes upon their incorporation into the skin.   
Exposure to UVA and the action spectra within the skin will differ 
according to the absorption spectra of the chromophores they target. 
The UV absorption spectra for psoralen and 8-MOP compounds have 
been reported by Fowlks32 as having maxima in their  absorption 
spectra at approximately 220nm, 245nm, and 295nm (with a shoulder at 
330nm) for psoralen and  220nm, 250nm, and 310nm for 8-MOP.  
This study has established the erythemal action spectrum for bath or 
soak PUVA therapy for the first time, using an aqueous application of 
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psoralen as is used in routine clinical practice. In all volunteers, the 
action spectrum for 8-MOP induced erythema has its maximum activity 
(peak sensitivity) at 325nm.  All volunteers showed a similar trend 
across the wavelengths studied irrespective of skin type.  The PUVA 
induced clearance of psoriasis study by Farr et al.1655 involving 24 
patients with psoriasis, found that lamps with peak emission at 325nm 
were significantly superior to lamps with peak emission at 352nm or 
370nm for clearance of psoriasis over a 6-week period. Equally 
erythmogenic doses from each of the lamps were used. They 
concluded that the therapeutic action spectrum for PUVA is not the 
same as the action spectrum for PUVA erythema. However, our topical 
PUVA erythema action spectrum would more closely agree with their 
psoriasis clearance action spectrum.  
The output of lamps conventionally used in PUVA whole-body units 
have peak emissions at around 365 nm.   A lamp with peak emission at 
325nm, would enable clearance of psoriasis with a lower cumulative UV 
dose over a shorter time period and would improve the efficacy and 
efficiency of PUVA. 
Our measured action spectrum for topical 8-MOP PUVA-induced 
erythema differs from previously published erythema action spectra34,38. 
This is most probably due to the use of strong solvents to deliver the 
psoralen in different concentrations, and differences in timings in 
application of psoralen and reading of erythema in previous studies. 
Our study was designed to test sensitisation of skin as would be 
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experienced after topical (bath) 8-MOP sensitisation as performed in 
routine clinical practice today. Our action spectrum was confirmed by 
the results of our previous study on MPD values established from PUVA 
lamps and TL-10 CFL. This result, of an independent study using 
different methodology, confirming the relative effectiveness of the two 
lamps used in the two MPD methods, is strong evidence to support the 
introduction of the simpler, safer hand-held MPD method into clinical 
phototherapy practice166.  It is well recognised that the effects of 
electromagnetic radiation on the skin vary in a continuous fashion with 
wavelength. The CIE defined three regions within the UV part of the 
spectrum as UVA, UVB and UVC. 
Therapeutically UVB and UVA are used in phototherapy. UVB has a 
greater erythemal effect on the skin than UVA by a factor of around 
1000. In many older studies on photodermatology the UV sources were 
poorly defined, and some may have been inadequately filtered. Thus 
effects that may have been wholly or partially attributed to UVA may 
have been in some ways ‗contaminated‘ by the effects of UVB leakage. 
This could be important especially in longer wavelength UVA spectral 
regions where psoralen-sensitisation of skin is less erythmogenic. In 
this study we were keen to isolate the effects of UVB from our observed 
outcome effect of erythema, and so we used a Schott glass WG320 
high-pass filter to remove UVB from all wavelength studied. Since 
320nm is on or very near the border between UVB and UVA, we used 
325nm as our shortest wavelength.    
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Future studies could examine the response of psoralen sensitisation 
into the UVB, where Diffey and Farr165 demonstrated an extra 
sensitisation due to psoralen sensitisation. 
 
 
As such, our action spectrum is most relevant in establishing the 
potential effectiveness of novel lamps for PUVA phototherapies. 
This enables accurate assessment of new UVA lamps, such as light 
emitting diodes or plasma screen sources, which may be used for 
PUVA in the future.  Larger studies are required to assess differences in 
the PUVA erythema action spectrum between skin types.
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Topical Regimen in Hand/Foot PUVA 
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Background 
Palmoplantar dermatoses such as psoriasis or eczema are frequently 
encountered in dermatology.  They are often resistant to conventional 
topical therapies including coal tar preparations, topical corticosteroids, 
vitamin D analogues and anthralin.  There is no consensus about the 
ideal topical phototherapy to treat palms and soles.  Accurate 
comparison of response to topical PUVA between studies is hampered 
by variations in topical psoralen formulation, time between 
application/immersion of psoralen and illumination with UVA, UVA 
regimes and clinical response grading.   
In the right-left comparison study by Shephard et al.167  37 patients 
received ethanolic 0.15% 8-MOP lotion for the right hand/foot and 
aqueous 1mg/L 8-MOP for the left hand/foot.  The treated areas were 
exposed to UVA within 20 minutes of bathing or painting thrice weekly.  
Although both therapies were effective, the concentration of 8-MOP 
within the ethanolic lotion was 1000 times greater than in the bath 
(aqueous) PUVA regimen.  Patients required a lower cumulative dose 
of UVA.  The authors advocated aqueous PUVA for fissured skin and 
ethanolic 8-MOP lotion for hyperkeratotic dermatoses. 
Comparison studies involving the use of 0.0006% Psoralen cream 
(0.0006% 8-MOP containing water in oil emulsion (30% H2O)) to 
0.5mg/L 8-MOP solution (bath-PUVA) four times/ week168, 0.005% 8-
MOP gel to 1.0mg/L 8-MOP solution three to four times/week169 were 
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undertaken.  Despite variations in the time of soaking in PUVA solution 
or applying Psoralen cream or gel to acral surfaces followed by 
illumination with UVA, the results were equivocal.  Potential advantages 
of PUVA-gel therapy are the ability to photosensitise select skin areas, 
reduction of organizational efforts and expenses compared to bath-
PUVA. 
In 1994, Hawk and Le Grice retrospectively reviewed the efficacy of oral 
PUVA versus topical PUVA in the treatment of chronic hand and foot 
dermatoses over an eighteen-month period and found both treatment 
modalities equally effective.170  There is weak evidence to support 
superiority of oral PUVA versus bath PUVA.  The study conducted by 
Hofer et al.171 involved 8 patients with moderate-to-severe palmoplantar 
psoriasis treated thrice weekly for 4 weeks with either bath PUVA (one 
side) or oral PUVA (contralateral side).  Although there was no 
significant difference in reduction of severity indices (erythema, 
infiltration, scaling and vesicles) between the two modalities, the 
authors claim that there was a significantly better effect in lesions 
treated with oral PUVA compared with soak PUVA. 
Both a retrospective safety and efficacy study comparing oral PUVA to 
nbUVB172 and a prospective comparison of PUVA paint to nbUVB in the 
treatment of palmoplantar psoriasis173, each delivered thrice weekly, 
show that PUVA is superior to nbUVB in achieving improvements and 
clear skin.  However, nbUVB was associated with less adverse effects 
CHAPTER FOUR 
 
107 
 
compared to oral / topical PUVA.  This should remain a treatment option 
reserved for patients who experience phototoxic reactions to psoralens. 
The British Photodermatology Group (BPG) guidelines52 for topical 
PUVA recommend a delay of 30 minutes between soaking hands 
and/or feet and UVA irradiation in the treatment of palmar-plantar 
dermatoses. This recommendation is based on a single study50 , and is 
not universally adopted. This study presented measurements of the 
time course of erythema on 6 healthy subjects, noting the presence, but 
not severity, of erythema at 72 hours after a single standardised dose of 
UVA on psoralen-sensitised hands and feet. Peak sensitivity occurred 
between 30 – 40 mins after removal from the psoralen solution.  The 
authors concluded that it seemed reasonable to suppose that the 
therapeutic response of palmoplantar psoriasis would follow a similar 
time course, although this remained to be demonstrated. A study 
involving 30 patients (10 patients had eczema, 13 had psoriasis (plaque 
or hyperkeratotic), 6 had psoriasiform dermatitis and one had localised 
pustular psoriasis) found that 10% of the patients demonstrated a 
marked benefit from delaying irradiation (of whom two of three had 
hyperkeratotic psoriasis)174.  A larger study is required to investigate the 
relationship between hyperkeratosis and improved response to delayed 
irradiation.  This remains the case to this day. 
A 30-minute wait between soaking hands and/or feet and UVA 
irradiation is inconvenient and time-consuming, and many centres claim 
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adequate clinical response with no delay between soak and irradiation. 
This study aims to demonstrate whether the clinical response follows 
the demonstrated erythemal response, and whether this holds for a 
larger population with palmoplantar dermatoses (both psoriasis and 
eczema). 
Rationale 
In the absence of controlled studies to provide a universally accepted 
protocol for the treatment of palmoplantar dermatoses with topical 
PUVA, phototherapy units throughout the UK have adopted protocols 
varying in the length of time-lapse between immersion and illumination, 
from 0 to 30 minutes.  This study aims to determine whether the time-
lapse affects the treatment outcome.  If there is no difference between 
outcomes, this could have widespread implications in the time taken to 
treat patients and the number of patients that could be treated. 
 
4.2 Aims 
To determine the optimal treatment protocol for treating hand and 
foot dermatoses with topical PUVA in terms of delay between soak 
and UVA exposure and reduction of severity, or time to clearance. 
To assess safety in terms of the number of treatment induced 
adverse events reported for each regimen. 
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4.3 Design of the Study 
Sample size calculation: 
This was a within patient study to evaluate the efficacy of two treatment 
regimens.   
All published studies of hand/foot soak PUVA present data on time to 
clearance and reduction in severity scores for groups of independent 
patients. There is thus no previous work to suggest a within-patient 
standard deviation of treatment outcomes. Therefore an assumption of 
time to clearance of 40 treatments, with a standard deviation of 4 will be 
used to estimate the number of subjects required. Using a two-sided 
test, with a power of 0.8 and setting significance at p = 0.05, 34 patients 
would be required). 
If we chose to use a published severity score, then a study169 indicates 
a typical score of 26.5, SD 11, reducing to 1.5 after clearance. If we 
assume a significant difference in score between treatment regimens of 
5, then the number of subjects required is 41. We therefore chose to 
recruit 42 patients. 
The study was a within-patient, randomised, assessment-blinded (i.e. 
single-blind), comparison of 2 treatment regimens in 42 patients with 
eczema or psoriasis of either their hands or feet who have been 
referred for topical PUVA therapy. 
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Two sites (either hands or feet) were pre-treated with topical psoralen 
according to the local (Newport) protocol.  One site was then illuminated 
immediately with UVA light and the other site was illuminated 30 
minutes after removal from PUVA solution.  Assessments of symptoms 
and signs (Erythema, Thickness, Scaliness, Fissures, Pruritus/Pain, 
Vesiculation and Oedema) and Physicians Global Assessment, by an 
independent assessor, were made before the first treatment, then every 
4 weeks throughout the treatment period and at the final visit.  
Photographs will be taken at baseline and final visits. 
 
 4.4 Ethical Approval 
Before commencement of this study, ethical approval was obtained 
from the South East Wales Local Research Ethics Committee.  
Approval was also sought and obtained from the Aneurin Bevan 
Healthcare NHS Trust Scrutiny and Risk Review Committee. (Ref No. 
12/WA/0043) 
 
4.5 Written Informed Consent 
An information sheet describing the study and procedures to be 
performed was supplied to each patient prior to starting the study.  The 
study was fully explained and patients were then required to provide 
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their written, witnessed consent.  A copy of the information sheet and 
consent form is included in appendix III.  
4.6 Study Subjects 
42 patients with palmoplantar psoriasis / eczema were planned to be 
recruited.  All patients will have been referred in the normal way to the 
phototherapy unit at St.Woolos Hospital, Newport, or the phototherapy 
unit at University Hospital of Wales, Cardiff. 
4.61 Inclusion criteria 
1. Aged at least 16 years. 
2. Has either eczema or psoriasis with involvement of either 
both hands or both feet 
3. Has signed the consent form after the nature of the study has 
been fully explained 
4.62 Exclusion criteria 
1. Has pustular psoriasis of the hands / feet as this tends to be 
recalcitrant to topical PUVA. 
2. Significant concurrent illness likely to interfere with the study 
including malignancy. 
3. Use of medication likely to interfere with the study, including 
immunosuppressant and photosensitising drugs. 
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4. Pregnant or lactating females 
5. Unwilling or unable to give written consent. 
4.7 Method  
Patients had their Boston Skin Phototype assessed by the phototherapy 
nurse practitioner, as is normal practice before a course of treatment. 
The first PUVA dose was based on the Phototype according to the 
treatment dose protocol common to Cardiff and Newport.  
Treatment 
The affected sites (both hands and/or both feet) were pre-treated by 
local immersion (8-MOP at a concentration of 3mg/L and a temperature 
of 37°C for 15 minutes), to sensitise them to UV light. 
The allocation of right or left hand/foot to receive treatment A or B will 
be randomised.  A randomisation schedule was calculated using the 
―random‖ function in Microsft Excel.  The code was kept by a team 
member (CE) and each subject was allocated left or right, wait or 
immediate UVA exposure according to a printed table supplied by CE.  
Treatment A:  One side was illuminated immediately after immersion 
was complete. 
Treatment B:  The other side was illuminated 30 minutes after 
immersion was complete. Treatments were continued until clearance 
was achieved, or for a maximum of 30 treatments for hands and 40 
treatments for feet. 
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Assessments 
Severity assessments using validated severity tools –for psoriasis and 
eczema (assessing global severity, Erythema, Thickness, Scaliness, 
Fissures, Pruritus/Pain, Vesiculation and Oedema)  were made by an 
independent assessor at baseline, every 4 weeks throughout treatment, 
and at the final visit.   The primary efficacy measure for therapeutic 
response was whether a delay of 30 minutes prior to illumination with 
UVA was therapeutically effective as determined by the physician‘s 
global assessment (PGA) of overall chronic hand dermatosis performed 
at baseline, every 4 weeks throughout treatment schedules and at the 
final visit. PGA criteria, based on a previous study175 were defined as 
follows: 
Global Severity:  
0 = no symptoms of disease  
1 = very slight symptoms of disease  
2 = slight symptoms of disease  
3 = moderate symptoms of disease  
4 = severe symptoms of disease  
5 = very severe symptoms of disease  
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Symptoms included in this assessment included: Scaling, redness, 
extent and severity of hyperkeratosis (thickening), patient-reported itch, 
fissuring, area of involvement.  The extent of disease was estimated by 
the physician as the total percentage involvement of the palms. 
Secondary efficacy measures were the modified total lesion symptom 
score (mTLSS), The mTLSS was adapted from a previous TLSS 
scale,176,177and calculated as the sum of scores (0 = absent, 1 = mild, 2 
= moderate, 3 = severe) assigned by the physician for the following 7 
parameters: erythema, oedema, vesicles, desquamation, 
hyperkeratosis, fissures, and pruritus/pain. 
 
Standardised digital photographs were taken of each site at baseline 
and final visits.
 
4.8 Results  
Eight patients (4 females and 4 males) were recruited for the study.  
Their ages ranged between 44 – 67 years (mean 52 years).  One 
patient withdrew from the study.  The remaining seven patients had 
phototypes as follows: two patients – skin type II, five patients – skin 
type III.  Three patients had eczema and four patients had psoriasis 
affecting their hands/feet. 
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Figure 4.1 Study Flow Chart 
 
Assessed for eligibility (n= 8 ) 
Analyzed  (n= 4.5 )* 
 Excluded from analysis 
(discontinued trial) (n=1 ) 
Lost to follow-up (n= 0  ) 
Discontinued (n=1) 
5 HAND  
ECZEMA (n = 3) 
PSORIASIS (n = 2) 
 
 
 
 
Lost to follow-up  (n= 0 ) 
Discontinued intervention  (n=0  
) 
2 FOOT 
ECZEMA (n = 1) 
PSORIASIS (n = 1) 
. 
 
Analyzed  (n= 2.5 )* 
 Excluded from analysis (n=0 ) 
 
Within-patient 
randomised 
treatment allocation 
left-right treatment  
Analysis 
Follow-Up 
Recruited (n= 8 ) 
Enrolment 
Immediate illumination 
following soak 
Delay 30 minutes following 
immersion 
Data Analyzed for Primary End Point (n=7) 
1 HAND & FOOT 
PSORIASIS 
* H/F patient hands and feet 
treated as separate sites 
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The results show that patients with both hand/foot eczema and 
psoriasis improved during the course of treatment with regards to the 
Total Score (Erythema, Thickness, Scaliness, Fissures, Pruritus/Pain, 
Vesiculation and Oedema)  and Physician‘s Global Assessment. 1 
patient with eczema and 1 patient with psoriasis were clear by week 20. 
Visit; LS Means
Wilks lambda=.57023, F(10, 130)=4.2155, p=.00004
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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Figure 4.2 Mean Total Score with visit number 
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Visit; LS Means
Wilks lambda=.57023, F(10, 130)=4.2155, p=.00004
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Figure 4.3 Mean Physician Global Score with visit number 
 
The analysis of variance test showed that the length of treatment had a 
significant effect on the total score.  There was a statistically significant 
reduction in Physician‘s Global Assessment and Total score as length 
of treatment progressed and assessments undertaken at 4-weekly 
intervals.  
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Table 4.1 Univariate Test of Significance for Physician Global Score 
Univariate Tests of  Signif icance for Physician Global Score (Deana Hand Foot PUVA Study (2))
Sigma-restricted parameterization
Ef fective hypothesis decomposition
Ef fect
SS Degr. of
Freedom
MS F p
Intercept
Visit
Delay
Error
238.5645 1 238.5645 197.3233 0.000000
51.1351 5 10.2270 8.4591 0.000003
0.3205 1 0.3205 0.2651 0.608234
85.8392 71 1.2090
 
 
Table 4.2 Univariate Test of Significance for Total Score 
Univariate Tests of  Signif icance for Total score (Deana Hand Foot PUVA Study (2))
Sigma-restricted parameterization
Ef fective hypothesis decomposition
Ef fect
SS Degr. of
Freedom
MS F p
Intercept
Visit
Delay
Visit*Delay
Error
1771.629 1 1771.629 168.0228 0.000000
376.389 5 75.278 7.1394 0.000018
3.494 1 3.494 0.3313 0.566672
10.063 5 2.013 0.1909 0.965126
759.167 72 10.544  
 
The results indicate however that there was no statistically significant 
difference in the Total Score and Physician‘s Global Assessment 
between waiting for 30 minutes or immediate UVA illumination. 
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Visit*Delay; LS Means
Wilks lambda=.97505, F(10, 130)=.16526, p=.99820
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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Figure 4.4 Comparing immediate and 30 minute delay before UVA 
illumination with Total Score 
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Figure 4.5 Comparing immediate and 30 minute delay before UVA 
illumination with Physician Global Assessment 
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4.9 Discussion 
The results of this left-right within patient comparison study show that 
patients with hand/foot eczema and psoriasis continued to show 
improvements with soak PUVA during the study period 24 weeks.  Two 
patients were completely clear of dermatoses at 20 weeks, the 
remainder showed significant improvement.  Although there was no 
statistically significant difference between waiting for 30 minutes after 
soaking in 8-MOP solution or immediate illumination with UVA, one 
patient with hyperkeratotic psoriasis affecting the soles of his feet 
showed a definite improvement after waiting for 30 minutes, in keeping 
with results from an earlier study173.  The sample size in this study is 
small and only seven subjects were included within the time-frame.   
Planned analyses of this study included multiple regression analysis for 
exploring the effect of diagnosis, site (hands/feet) and severity on the 
outcome measures. However, because of the failure to recruit the 
planned number of patients, these analyses are not feasible. It could be 
anticipated that the delayed exposure treatment may be more effective 
for hyperkeratotic (thick) disease, and if data from the planned number 
of subjects indicated that this was found, then a larger study would have 
been proposed to further confirm that finding. The patient who withdrew 
from the study had eczema affecting her hands; she was unable to wait 
for the thirty minutes duration required prior to UVA illumination due to 
personal commitments.  This patient also had a history of recurring 
episodes of infected hand eczema, potentially due to poor hand care, 
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requiring systemic antibiotics.  Recruitment for this study was slow and 
difficult. Potential reasons for this are the inconvenience and time-
commitments required for patients to attend their phototherapy sessions 
impacting on work and carer commitments.  Furthermore, if having 
achieved a satisfactory response to immediate UVA treatment following 
a soak in psoralen, there may be little incentive for patients to try a 
novel approach.   However, this study failed to anticipate the impact of 
alitretinoin on the number of patients with chronic vesicular hand 
eczema referred for PUVA therapy.  These patients have reduced 
significantly in number in the PUVA unit. 
This study also impacts on the phototherapy staff nurses who are 
required to deliver safe and effective treatment to an increasing patient 
population.    A delay of 30 minutes prior to treatment may have also 
been a contributing factor to poor recruitment.  
Recruitment could have been improved by targeting both the patients 
and the treating physicians.  If research nurses were available, then 
they could have administered the treatments, removing reluctance from 
busy phototherapists who did not usually treat with delayed exposure.  
Patient advertising in general dermatology clinics may have raised 
awareness and thus increased recruitment. Also, involving patient 
groups such as the Gwent Dermatology Patient Group may also have 
helped to raise the profile of the study. However, due to the study being 
run on multiple sites this was not attempted. 
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These strategies would have required the submission of an amendment 
for Ethical Opinion, and this would have introduced a delay in the study. 
 A larger study is required to formally investigate the efficacy of waiting 
for 30 minutes following a soak in 8-MOP prior to illumination with UVA. 
 
Due to the premature ending of this study because of poor recruitment, 
any statistical conclusions must be viewed with caution. The completed 
study, with the numbers actually analysed should be regarded as a pilot 
study, which may encourage the design of a larger study, perhaps 
concentrating on ―thicker‖ (hyperkeratotic) dermatoses, or the 
differences in effectiveness between acral (palmar/plantar) and other 
thinner (dorsal) sites.  Our results have been interpreted with caution 
since recruitment was poor and fewer than planned patients were 
included in the study. 
However, our limited results did confirm Desai and Halperns174 results 
that for non-hyperkeratotic conditions the 30 minute delay before UV 
exposure is unnecessary. 
For each of the clinical assessments (erythema, thickness, scaliness, 
pruritus/pain, fissures, vesiculation, oedema), for the composite total 
score (the sum of the individual symptom scores), and for the 
Physicians Global score we performed an Analysis of Variance for the 
effects of visit number and delay status.  The visit number (representing 
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progression into the treatment schedule) was highly significantly 
effective on influencing every outcome measure, with p-values less than 
0.001. None of the outcome measures was affected by delay status, 
with all p-values >0.9. 
This result is strongly supportive of the conclusion that delay was not 
significant in this study. 
However it must still be noted that we only had one patient with 
hyperkeratotic disease. So our strong conclusion may be stated that for 
non-hyperkeratotic skin conditions included in this study a delay 
between psoralen solution immersion and UVA exposure is 
unnecessary.  
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In the age of new systemic agents and increasingly targeted biologic 
therapies, is there still a role for PUVA in dermatology?  Biologics are 
predominantly used in the management of psoriasis and psoriatic 
arthritis. APRICOT is a UK double-blinded randomised placebo 
controlled trial, assessing the efficacy of Anakinra (anti IL-1) for 
palmoplantar pustulosis.  This trial was not published when the present 
trial was designed, and we have excluded pustular disease as this 
tends to be recalcitrant to topical PUVA. 
 However, all types of phototherapy are effective in a variety of 
dermatoses including atopic dermatitis, vitiligo, Cutaneous T-cell 
Lymphoma and polymorphic light eruption, to name but a few.    
There remains a paucity of studies directly comparing PUVA to 
biologics.  A comparative blinded study between these modalities would 
not be practical as PUVA induces erythema and pigmentation. A 
retrospective data analysis from a psoriasis registry comprising 172 
adults, between 2003 – 2010 by Inzinger et al.178 compared complete 
remission, PASI 90 and PASI 75 at completion of treatment for oral 8-
MOP and 5-MOP (median time 10.3 and 9.2 weeks respectively) to 
response to biologics at week 12.  Their results suggest that the primary 
efficacy of PUVA is superior to certain biologics. An important limitation 
of this study is the fact that clinical response to PUVA and biologics 
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were evaluated at different time points.  Optimal response to certain 
biologics e.g. Adalumimab, occurs beyond 12 weeks. 
The adverse effects of PUVA are well documented.  In contrast, side-
effects of biologics are only now becoming clearer.  These include 
invasive mycoses, progressive multifocal leukoencephalopathy, 
lymphoproliferative disorders and lupus-like syndrome.179   
A further strength of PUVA is that it may be used intermittently once 
remission has been achieved.  In contrast with biologics, the efficacy 
appears to decrease with prolonged use due to antidrug antibody 
formation180. This is not the case with PUVA where no evidence of 
antibody formation has been demonstrated.  
PUVA is clearly more time-consuming and sometimes inconvenient for 
patients. However, one study showed that PUVA guided by weekly 
MPD-testing in order to adjust the dose (i.e. MPD-guided PUVA), was 
successfully used in 89% of patients who reached PASI 75 within four 
weeks.181  
There remains widespread variation regarding how phototherapy is 
delivered in the U.K.   A questionnaire survey (Chapter 2) was 
completed by 72 individuals working in 43 U.K. phototherapy units 
across the United Kingdom, to assess routine practice concerning MPD 
testing prior to commencing PUVA phototherapy.  Only 14% of 
phototherapy centres surveyed routinely assessed MPD prior to 
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photochemotherapy.  The remaining centres found this practise too 
time-consuming, had no equipment to perform MPD testing or used the 
patient‘s skin phototype.   
CHAPTER FIVE 
Discussion 
128 
 
MPD testing serves a dual purpose, to minimise both the cumulative 
number of PUVA treatments and the incidence of adverse effects. It 
also establishes that sufficient psoralen is present in the patient‘s skin. 
If the extent of disease precludes MPD testing, the initial dose is based 
on skin phototype.   
The traditional method of assessing MPD is cumbersome and time 
consuming for both patients and staff and requires a separate source of 
UVA. In our unit, this used to take 15– 20 min. The difficulties (due to 
time required, equipment and training) of performing MPD testing 
discourage its widespread adoption.  Potential errors of the traditional 
method of assessing MPD using an open panel of UVA lamps including 
UV source nonuniformity due to curvature of the test site, patient 
movement and exposure timing errors may be resolved.  An easier, 
safer method of establishing the MPD may encourage more centres to 
perform this important check. 
A device that overcomes many of these difficulties is the MED tester 
used for UVB. This uses a compact fluorescence tube (CFL) in a 
handheld housing as the source and a UVB opaque template with 10 x 
1-cm-diameter apertures. The output of nine of these apertures is 
successively attenuated by a factor of 1.25 by steel shaver-type foils.   
A small handheld MED tester, being convenient and reliable, could be 
made available for MPD testing by replacing the UVB tube with a CFL 
TL-10 tube. The nearest equivalent CFL to a PUVA lamp is the Philips 
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TL-10 CFL, which has a narrower spectrum centred around a longer 
wavelength (370nm).  As PUVA photochemotherapy uses only psoralen 
as the sensitiser and only PUVA-designated lamps, it may be possible 
to establish a fixed factor to convert observed MPD using the TL-10 
CFL to a PUVA-equivalent MPD.     
The modified handheld MPD tester was calibrated for UV output using a 
Bentham DM150 spectroradiometer.   The DM150 was calibrated 
against a tungsten lamp which had a calibration from 250nm – 800nm 
traceable to the National Physical Laboratory.  The hand-held MPD 
tester required a 2 minute warm-up and 15 minute cool down between 
successive MPD tests.  Successive doses of UVA were delivered within 
a maximum time of 3 minutes 25 seconds.  MPD testing using the 
modified hand-held tester was safer and easier for both patients and 
staff to use.   
When comparing the handheld MPD results to the traditional PUVA 
panel MPDs, there was a close linear relation to the PUVA panel MPD 
results (Pearson‘s correlation Coefficient = 0.82).  However, the 
difference in MPD between the PUVA lamp and the modified handheld 
MPD tester (CFL TL-10 lamp) was much less than predicted from the 
PUVA action spectrum37. The erythemal effectiveness of the TL-10 
lamp, calculated using the PUVA erythema action spectrum of Cripps et 
al38, is 2·48, compared with the PUVA lamp effectiveness of 16·33 
(arbitrary units). Thus PUVA MPDs should be 0·15 of the TL-10 MPDs. 
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This suggested that formal re-evaluation of the erythema action 
spectrum for PUVA was warranted. 
Published research on topical psoralen ultraviolet A (PUVA) erythemal 
action spectrum used methods that do not reflect current clinical 
practice for psoralen sensitization. The study by Cripps et al.38 used 8-
methoxy psoralen at 1% dissolved in acetone and then in ethanol and 
applied (via pipette) directly to the skin of the lower dorsum trunk of 6 
Caucasian males.  This was then followed by irradiation with various 
wavelengths of UVA. No details were provided for the time between 
application of psoralen and UVA irradiation.   MPDs were read at 72 
hours.  Their findings were a peak sensitivity between 330-335nm for 8-
MOP, 6 times more effective than 365nm.  In the study by Buck et al.34 
there was a delay of between 1½ - 2 hrs between application of 1% 8-
MOP solution in chloroform and illumination with UVA. 
This scenario differs greatly from present clinical practice in the UK, 
where the skin is immersed in an aqueous solution of 8-
methoxypsoralen at 37ºC39 for 15 minutes, followed by UVA irradiation 
within 30 minutes.  The study by Schempp et al.40 showed there was a 
marked, significant reduction in erythema after 60 minutes delay 
between soaking in an 8-MOP bath and irradiation and no erythema 
was detected after 180 and 360 minute delay.   Man et al.57 showed that 
time to develop topical 8-MOP induced erythema had a broad peak at 
120 hours. However, MPD assessment during or beyond 120 hours is 
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best avoided due to confounding effects of the development of 
pigmentation.  Their recommendation was that topical 8-MOP MPD 
should be read four days (96 hours) after exposure.   
We therefore re-evaluated the PUVA erythema action spectrum using 
aqueous psoralen at 2.6mg/L concentration as is used routinely in 
current clinical practice in the UK and assessed MPDs at 96 hours.  We 
then used our action spectrum to estimate the ―PUVA equivalent‖ output 
of a range of UVA sources. This study has established the erythemal 
action spectrum for bath or soak PUVA therapy for the first time, using 
an aqueous application of psoralen as is used in routine clinical 
practice. In all volunteers, the action spectrum for 8-MOP induced 
erythema has its maximum activity (peak sensitivity) at 325nm.  All 
volunteers showed a similar trend across the wavelengths studied 
irrespective of skin type.  The PUVA induced clearance of psoriasis 
study by Farr et al.165 involving 24 patients with psoriasis, found that 
lamps with peak emission at 325nm were significantly superior to lamps 
with peak emission at 352nm or 370nm for clearance of psoriasis over a 
6-week period. Equally erythmogenic doses from each of the lamps 
were used. They concluded that the therapeutic action spectrum for 
PUVA is not the same as the action spectrum for PUVA erythema. 
However, our topical PUVA action spectrum would more closely agree 
with their psoriasis clearance action spectrum.  
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The output of lamps conventionally used in PUVA whole-body units, 
have peak emissions at around 365 nm.   A lamp with peak emission at 
325nm, would enable clearance of psoriasis with a lower cumulative UV 
dose over a shorter time period and would improve the efficacy and 
efficiency of PUVA.  Our measured action spectrum for topical 8-MOP 
PUVA-induced erythema differs from previously published erythema 
action spectra34,38.  
This is most probably due to the use of strong solvents to deliver the 
psoralen in different concentration, and differences in timings in 
application of psoralen and reading of erythema in previous studies. 
Our study was designed to test sensitisation of skin as would be 
experienced after topical (bath) 8-MOP psoralen sensitisation as 
performed in routine clinical practice today. Our action spectrum was 
confirmed by the results of our previous study on MPD values 
established from PUVA lamps and TL-10 cfl lamps (see Table 3.3 
PUVA effective ratio of typical PUVA sources used in clinical practice – 
Chapter 3). 
The table gives PUVA efficiency of the 2-ft fluorescent tube as 0.48, 
and that of the TL-10 UVA1 cfl lamp as 0.236. The ratio of these gives 
our prediction of the relative erythemal efficacy of the UVA1 lamp 
compared to the PUVA lamp. This value (0.236/0.48) is 0.49, which is 
almost exactly the value (0.48) that we measured from the MPD results 
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from our volunteer patients. This gives strong evidence of the validity of 
the action spectrum measured in this study. 
 
Regarding palmo-plantar dermatoses, just over two-thirds of 
respondents used topical 8-MOP rather than Psoralen gel.  
 
 
Figure 5.1Results of Questionnaire Survey  
Proportion of topical 8-MOP use compared to psoralen gel 
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Despite BPG Guidelines52  advocating a 30 minute wait following 
psoralen application and irradiation with UVA, results of the survey 
confirmed that there is a great deal of heterogeneity regarding time 
between immersion of acral surfaces in aqueous 8-MOP or application 
of psoralen gel to the areas and irradiation with UVA see figure 5.2.  
 
Figure 5.2. Variation in Time Interval between Immersion/Application of 
Psoralen and UVA Irradiation 
The principal reasons for this variation in clinical practise, as highlighted 
by the responders of this survey include preconceptions (based on 
personal opinion instead of evidence) by some clinical staff that PUVA 
is ineffective in the treatment of hand foot dermatoses. Another reason 
mentioned is the time required to wait for half an hour prior to exposing 
the limb to UVA, which is perceived as inconvenient by patients and 
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staff equally. Competing demands on clinical time to provide timely 
services to the patients has also been quoted as one of the basis for the 
varied practise.  These are also some of the reasons which adversely 
affected patient recruitment in this study as highlighted below. 
Although the numbers of patients included in the trial results (Chapter 4) 
are too small to draw firm conclusions from, they seem to suggest that 
patients with both hand/foot eczema and psoriasis improved during the 
course of treatment with regards to the Total Score (Erythema, 
Thickness, Scaliness, Fissures, Pruritus/Pain, Vesiculation and 
Oedema)  and Physician‘s Global Assessment.  In fact, there was a 
statistically significant reduction in Physician‘s Global Assessment and 
Total score as length of treatment progressed.  One patient with 
hyperkeratotic psoriasis affecting the soles of his feet showed a definite 
improvement after waiting for 30 minutes, in keeping with results from 
an earlier study174. 
Patient recruitment was challenging in this study. Potential reasons for 
the difficulty in recruitment of patients into this study include the time-
commitments essential for patients to attend their phototherapy 
sessions for extended periods (to accommodate for the delayed 
illumination of the control limb 30 minutes post Psoralen immersion) 
and the resulting impact on their other commitments.  Furthermore, if a 
patient previously had been treated with topical PUVA and achieved a 
satisfactory response to immediate UVA treatment following a soak in 
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psoralen, they declined participation in the trial as there was little 
incentive for them to try the delayed exposure method. Hence, lack of 
patient commitment with regards to time and trying out a new approach 
contributed significantly to the sub-satisfactory participant numbers in 
this study.  Simultaneously, lack of nursing staff to deliver this time 
intensive approach contributed to the recruitment difficulties.  The 
availability of more convenient alternative systemic treatment options 
for patients including oral Alitretinoin may also be a factor in patients 
declining participation in this study. 
This study also impacted on the phototherapy staff nurses who are 
required to deliver safe and effective treatment to an increasing patient 
population.    A delay of 30 minutes prior to treatment may have been a 
contributing factor to poor recruitment as mentioned above.   
 The  decline of psoralen ultraviolet A (PUVA) as treatment for chronic 
hand eczema (CHE) ignores the existing evidence and may deny some 
patients a useful treatment option. 
The licensing of alitretinoin for treatment-resistant CHE has greatly 
improved the outlook for patients with this disabling variant of eczema. 
The evidence for the efficacy of this drug is robust, with two 
multinational randomised controlled trials published, although their 
design would have been improved by inclusion of quality-of-life (QOL) 
outcomes.182  In the first study, 319 subjects were treated over a 12-
week period, and a significant dose-dependent improvement in disease 
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status was reported. However, 3 months after discontinuation of 
treatment, the rate of relapse was 26%, independent of dose.183 In the 
subsequent study, 1032 subjects were treated over a 24-week period; 
47.7% of subjects had clear or almost clear skin by week 24of treatment 
with 30 mg alitretinoin, compared with 16.6% for placebo (P < 0.001). A 
confounding factor was the discontinuation of treatment halfway through 
the study in a subgroup of responders.183 Median time to relapse was 
5–6 months.184 The main adverse events (AEs) reported in these two 
studies were headache, dry mouth and erythema. In addition, increases 
in cholesterol and triglycerides occurred, as did asymptomatic changes 
in levels of thyroid-stimulating hormone. AEs were generally dose 
dependent and reversible.  It is clear from these studies that alitretinoin 
is not effective in all cases of CHE, that many patients relapse after 
withdrawal of treatment, and that 10% of patients receiving 30 mg 
withdrew from the trial because of AEs. 182,183,184 
What alternative treatments are available for this group of alitretinoin 
non-responders and for women of child-bearing age, for whom systemic 
retinoids are contraindicated?  Topical PUVA is one option for 
treatment-resistant CHE. Unlike topically applied PUVA in the form of a 
gel, lotion or cream preparation, soak PUVA allows a more uniform 
cutaneous absorption of 8-methoxypsoralen (8-MOP); the macerated 
stratum corneum of CHE facilitates penetration of 8-MOP, and carries a 
lower risk of phototoxic reactions and persistent hyperpigmentation than 
CHAPTER FIVE 
Discussion 
138 
 
topically applied psoralens.185 Furthermore, patients with CHE do not 
have several courses of topical PUVA; the cumulative doses are usually 
low, and there is no evidence for a skin cancer risk after topical hand ⁄ 
foot soak PUVA. 
In a prospective trial of 38 subjects with CHE treated with PUVA three 
times per week, 53% patients were disease-free after an average of 19 
sessions (range 8–42) with patients receiving treatment,186 and 29% of 
patients had improved after an average of 12 sessions (range 1–22 
weeks). Maintenance was given once a week for most patients and one 
patient had maintenance twice a week.186 Disease-free patients 
remained in remission for a median period of 10 months.186 When 
relapse occurred in these subjects it was reported to be more benign 
than previously.186  
Grattan et al. reported a double-blind randomised within-patient trial on 
15 subjects, comparing topical PUVA against UVA for the treatment of 
vesicular CHE. There was improvement in both hands during the 8-
week treatment period (P < 0.05), and they remained subjectively and 
objectively better during the 8-week follow-up, with no significant 
difference between treatment methods at any stage. At follow-up 18 
months later, four patients reported that their eczema was healed. The 
authors concluded that UVA alone may be beneficial for CHE.187 
In a further study, narrow-band UVB was compared with paint PUVA in 
a 9-week prospective, left–right comparison study of 15 patients with 
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the dry and dyshidrotic types of CHE. Both groups showed clinical 
improvement, with little difference between treatment methods.188 
A retrospective study on localised topical and systemic 
photochemotherapy for chronic hand and foot dermatoses of 40 
patients noted no difference in efficacy between treatment methods. 
However, the study population was mixed, and included patients with 
psoriasis, palmoplantar pustulosis and CHE. This more recent study 
included QOL measurements, unlike the earlier studies.170  A recent 
open-label RCT compared the efficacy of home-administered oral 
PUVA with hospital-delivered bath PUVA for CHE in 150 patients.  Both 
groups responded well, and there was no difference between treatment 
groups after 10 weeks and at follow-up 8 weeks later.189  There still 
remains a role for other systemic immunosuppressant treatments 
including azathioprine, ciclosporin, methotrexate and mycophenolate 
mofetil in the management of refractory cases of hand eczema.  
Although one study190 demonstrated prolonged remission for one year 
in 74% of patients treated with a 6-week course of ciclosporin 
3mg/kg/day, other studies showed high relapse rates shortly following 
discontinuation of ciclosporin191,192  
Methotrexate, at doses between 15 – 22.5mg/week, was shown to be 
effective in 5 patients with severe recalcitrant dyshidrotic eczema when 
used as adjunctive therapy.  Patients were able to reduce or 
discontinue systemic steroid use.193   
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Mycophenolate mofetil 2 – 3 grams/day has been successfully used to 
treat a 39 year-old male with severe dyshidrotic eczema.  Long-term 
remission was achieved and maintained after one year of treatment.194 
Although unlicensed, clobetasol propionate cream 60% mixed with the 
penetrant propylene glycol 40% under polythene occlusion to the palms 
overnight for two or three nights until clear and at the first sign of 
recurrence introduced by Dr. Gerald Levene at St. John‘s Hospital, 
London is extremely effective. It leads rapidly to complete remission 
without adverse effects and if used very early during the expected 
recurrence after a week or so clears again with usually only one night‘s 
use, leading eventually to longer and longer remissions.(Personal 
communication John Hawk). 
The paucity of data regarding the most clinically effective treatment for 
severe hand eczema following suboptimal response to potent topical 
steroid ointments prompted the calls for the ALPHA study.  This 
prospective UK RCT directly compares Alitretinoin 30mg (once daily) to 
immersion PUVA (twice weekly) to establish which of these two 
treatments is the most effective in the management of particular types 
of hand eczema. Prior to commencing treatment, patients will be tested 
for fillagrin mutations. The ALPHA study will examine both the short 
term and longer term effectiveness of each treatment modality in terms 
of remission of hand eczema and subsequent flares. 
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PUVA remains an important treatment option for those patients who 
have a contraindication to retinoids and for those who fail to respond or 
are intolerant to alitretinoin, or who relapse early after alitretinoin 
treatment. The efficacy of a retinoid + PUVA compared with alitretinoin 
should now be examined in patients who fail to respond to either 
therapy given alone. 
 
 
 
Recommendations 
 The semi-automated MPD tester was shown to be 
safe, convenient and reliable compared to the 
traditional ‗open-panel‘ method of UVA lamps.  This 
may be used in a larger cohort of patients undergoing 
topical PUVA treatment for other dermatoses, for 
example atopic dermatitis.   
 Re-evaluation of the erythema action spectrum of 
topical psoralen sensitised skin has shown that peak 
sensitisation occurred at 325nm.  Treatment of 
patients with 325nm lamps need to be explored as this 
has shown in controlled study environments to be 
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more efficacious than the standard UVA phototherapy 
cabins emitting longer wavelengths. 
 Further studies are needed to evaluate the topical 
regime used in hand/foot dermatoses (eczema or 
psoriasis), particularly in patients with hyperkeratotic 
dermatoses. It is possible that a delay of 30 minutes 
following immersion in topical psoralen followed by 
UVA illumination may be more successful for such 
patients. However, completion of the current study is 
necessary to formally investigate this hypothesis. 
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